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Reactive oxygen species (ROS) have been known to cause damage to a 
variety of biological substances especially DNA. The damage to DNA is known 
to be mutagenic and probably represents a major natural hazard for the genomic 
stability of living cells. The most reactive of the ROS is the hydroxy! radical 
(•OH) which can attack virtually any target molecule it encounters. These are 
formed in biological systems via ionizing radiations or through the Fenton 
reaction. The hydroxyl radical may attack DNA at either the sugar or the base, 
ultimately causing DNA single strand breaks and formation of altered bases. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
of unknown etiology characterized by the presence of autoantibodies in 
circulation that bind to numerous self antigens such as DNA, RNA, 
ribonucleoproteins and histones. Although antibodies that react with B-
conformation are found in sera of patients with SLE, B-DNA per se is a poor 
immunogen. On the other hand various other conformations of DNA such as 
right handed A-form and left handed Z-form are potentially immunogenic. Also, 
chemically modified DNA has been found to result in the production of 
antibodies. Thus it could be suggested that a conformational variant of B-form 
is essential for the generation of anti-DNA antibodies. 
In the present study purified native calf thymus DNA was modified with 
hydroxyl radical generated by UV irradiation in presence of hydrogen peroxide. 
UV spectroscopy of the ROS-modified DNA revealed a significant decrease in 
the absorbance at 260 nm as compared to its corresponding unmodified control. 
Thermal denaturation study showed a net decrease of 13.5°C in the Tm value 
for ROS-DNA indicating a partial destruction of its secondary structure. The 
single strand breaks induced in DNA as a result of modification by ROS were 
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detected by alkaline sucrose gradient centrifugation and nuclease SI sensitivity 
assay. In addition to the alterations within sugar phosphate backbone, hydroxy! 
radical was also found to induce DNA base modifications. Ion exchange 
chromatography on DEAE-Sephadex A-25 column showed the modification of 
thymine to the greatest extent followed by guanine, cytosine and adenine. 
In addition to the modification of DNA by ROS, individual bases adenine, 
thymine and the synthetic homopolymers poly(dA) and poly(dT) were similarly 
modified with ROS. UV absorption profile exhibited drastic changes in ROS-
modified adenine and thymine, while homopolymers poly(dA) and poly(dT) 
modified with ROS showed substantial decrease in UV absorbance at 260 nm. 
Monoclonal antibodies raised against 400 bp ROS-DNA were used for 
further studies. A high binding monoclonal (PjCjjDg) antibody was chosen. The 
monoclonal antibody showed a high inhibition of 84% when ROS-DNA was used 
as inhibitor and a lower inhibition of 60% with 200 bp ROS-DNA. The antibody 
also showed cross-reactivity with nDNA, showing an inhibition of 65%. The 
specificity was further ascertained using a variety of inhibitors. Among the 
bases, ROS-thymine was found to be the potent inhibitor of anti-ROS-DNA 
antibody binding to the antigen, followed by ROS-guanine. Their unmodified 
forms were non-inhibitory. Similarly, the other DNA bases i.e. cytosine and 
adenine were ineffective inhibitors in both their native and modified forms. The 
homopolymer poly(dT) modified with ROS as well as ROS-thymidine exhibited 
substantial inhibition although their native forms were non-inhibitory. Some 
degree of cross reactivity was also observed with some synthetic polynucleotides 
having A-, B- and allied conformations although to a lesser degree than to the 
ROS modified epitopes. Thus it appears that the monoclonal antibodies are 
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specific towards ROS-epitopes and some amount of cross reactivity seen with 
B-DNA and synthetic polynucleotides could be due to certain shared/common 
antigenic determinants. 
The participation of lysine residues in the immunochemical reactivity of 
anti-ROS-DNA antibodies was investigated by modifying the free amino groups 
of lysine residues with acetic anhydride. It was found that the modification of 
lysine residues paralleled loss in antibody activity, thus suggesting the role of 
lysine residues in the antigen binding site of the immunoglobulin molecule. 
In the present study, SLE sera from patients having high titre anti-DNA 
autoantibodies were studied for their recognition of ROS-DNA. The binding 
specificity of SLE autoantibodies was analysed by inhibition ELISA and gel 
retardation assay. The ROS-DNA showed an appreciable binding with all of the 
SLE sera tested with enhanced inhibitions in most of the cases compared to the 
native conformer. In addition, it was observed that ROS-thymine was an 
effective inhibitor of anti-DNA autoantibody binding to the antigen, as was 
ROS-poly(dT) but to a lesser extent. In contrast, their unmodified forms were 
not inhibitory and so was adenine as well as ROS-adenine. The homopolymer 
poly(dA) and ROS-poly(dA) also failed to show any binding with the SLE 
autoantibodies. The binding patterns of these autoantibodies obtained from 
different patients indicate their recognition of altered/modified conformation. 
The results were further confirmed by dot blot assay and gel retardation assay. 
Monoclonal anti-ROS-DNA antibody was used as a probe to assess 
oxidative DNA damage in SLE patients. DNA isolated from the lymphocytes of 
SLE patients was used as an inhibitor in competition ELISA. It was found that 
five out of the eight patients tested showed inhibition of monoclonal antibody 
IV 
binding to ROS-DNA, thus suggesting the presence of oxidative lesions in these 
patients which are being recognized by the monoclonal antibodies. 
ROS-DNA was found to be a potent immunizing stimulus, inducing high 
titre anti-ROS-DNA antibodies in rats as evaluated by direct binding ELISA. 
Kidney sections of the immunized rats were tested for immune complex 
deposition by immunofluorescence. There was found to be a concentration of 
immune complexes in the glomeruli of the kidneys which was exhibited as apple 
green fluorescence. The immune complex deposition may cause kidney 
inflammation and tissue destruction. This could be correlated to acute stage of 
lupus nephritis wherein deposition of immune complexes between DNA and 
antibodies to DNA has been considered to elucidate inflammatory reaction. 
In conclusion it could be summed that native DNA modified by ROS is 
rendered immunogenic in rats and immune complex deposition in kidney could 
be detected. Also monoclonal antibodies were found to be specific towards ROS-
epitopes with special affinity for ROS-thymine and ROS-poly(dT). A similar 
observation was made when anti-DNA autoantibodies from SLE sera were 
probed for their binding with other inhibitors besides native DNA. Thereby 
suggesting that probably thymine in DNA upon modification with hydroxyl 
radical undergoes conformational changes rendering DNA immunogenic leading 
to the production of circulating antibodies cross reacting with native DNA in 
SLE. Monoclonal antibody was also found to be a good probe for assessing 
oxidative damage to the human genome in systemic lupus erythematosus. 
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Reactive oxygen species (ROS) have been known to cause damage to a 
variety of biological substances especially DNA. The damage to DNA is known 
to be mutagenic and probably represents a major natural hazard for the genomic 
stability of living cells. The most reactive of the ROS is the hydroxyl radical 
(•OH) which can attack virtually any target molecule it encounters. These are 
formed in biological systems via ionizing radiations or through the Fenton 
reaction. The hydroxyl radical may attack DNA at either the sugar or the base, 
ultimately causing DNA single strand breaks and formation of altered bases. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
of unknown etiology characterized by the presence of autoantibodies in 
circulation that bind to numerous self antigens such as DNA, RNA, 
ribonucleoproteins and histones. Although antibodies that react with B-
conformation are found in sera of patients with SLE, B-DNA per se is a poor 
immunogen. On the other hand various other conformations of DNA such as 
right handed A-form and left handed Z-form are potentially immunogenic. Also, 
chemically modified DNA has been found to result in the production of 
antibodies. Thus it could be suggested that a conformational variant of B-form 
is essential for the generation of anti-DNA antibodies. 
In the present study purified native calf thymus DNA was modified with 
hydroxyl radical generated.by UV irradiation in presence of hydrogen peroxide. 
UV spectroscopy of the ROS-modified DNA revealed a significant decrease in 
the absorbance at 260 nm as compared to its corresponding unmodified control. 
Thermal denaturation study showed a net decrease of 13.5°C in the Tm value 
for ROS-DNA indicating a partial destruction of its secondary structure. The 
single strand breaks induced in DNA as a result of modification by ROS were 
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detected by alkaline sucrose gradient centrifugation and nuclease SI sensitivity 
assay. In addition to the alterations within sugar phosphate backbone, hydroxyl 
radical was also found to induce DNA base modifications. Ion exchange 
chromatography on DEAE-Sephadex A-25 column showed the modification of 
thymine to the greatest extent followed by guanine, cytosine and adenine. 
In addition to the modification of DNA by ROS, individual bases adenine, 
thymine and the synthetic homopolymers poly(dA) and poIy(dT) were similarly 
modified with ROS. UV absorption profile exhibited drastic changes in ROS-
modified adenine and thymine, while homopolymers poly(dA) and poly(dT) 
modified with ROS showed substantial decrease in UV absorbance at 260 nm. 
Monoclonal antibodies raised against 400 bp ROS-DNA were used for 
further studies. A high binding monoclonal (PgCjjD^) antibody was chosen. The 
monoclonal antibody showed a high inhibition of 84% when ROS-DNA was used 
as inhibitor and a lower inhibition of 60% with 200 bp ROS-DNA. The antibody 
also showed cross-reactivity with nDNA, showing an inhibition of 65%. The 
specificity was further ascertained using a variety of inhibitors. Among the 
bases, ROS-thymine was found to be the potent inhibitor of anti-ROS-DNA 
antibody binding to the antigen, followed by ROS-guanine. Their unmodified 
forms were non-inhibitory. Similarly, the other DNA bases i.e. cytosine and 
adenine were ineffective inhibitors in both their native and modified forms. The 
homopolymer poly(dT) modified with ROS as well as ROS-thymidine exhibited 
substantial inhibition although their native forms were non-inhibitory. Some 
degree of cross reactivity was also observed with some synthetic polynucleotides 
having A-, B- and allied conformations although to a lesser degree than to the 
ROS modified epitopes. Thus it appears that the monoclonal antibodies are 
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specific towards ROS-epitopes and some amount of cross reactivity seen with 
B-DNA and synthetic polynucleotides could be due to certain shared/common 
antigenic determinants. 
The participation of lysine residues in the immunochemical reactivity of 
anti-ROS-DNA antibodies was investigated by modifying the free amino groups 
of lysine residues with acetic anhydride. It was found that the modification of 
lysine residues paralleled loss in antibody activity, thus suggesting the role of 
lysine residues in the antigen binding site of the immunoglobulin molecule. 
In the present study, SLE sera from patients having high titre anti-DNA 
autoantibodies were studied for their recognition of ROS-DNA. The binding 
specificity of SLE autoantibodies was analysed by inhibition ELISA and gel 
retardation assay. The ROS-DNA showed an appreciable binding with all of the 
SLE sera tested with enhanced inhibitions in most of the cases compared to the 
native conformer. In addition, it was observed that ROS-thymine was an 
effective inhibitor of anti-DNA autoantibody binding to the antigen, as was 
ROS-poly(dT) but to a lesser extent. In contrast, their unmodified forms were 
not inhibitory and so was adenine as well as ROS-adenine. The homopolymer 
poly(dA) and ROS-poly(dA) also failed to show any binding with the SLE 
autoantibodies. The binding patterns of these autoantibodies obtained from 
different patients indicate their recognition of altered/modified conformation. 
The results were further confirmed by dot blot assay and gel retardation assay. 
Monoclonal anti-ROS-DNA antibody was used as a probe to assess 
oxidative DNA damage in SLE patients. DNA isolated from the lymphocytes of 
SLE patients was used as an inhibitor in competition ELISA. It was found that 
five out of the eight patients tested showed inhibition of monoclonal antibody 
IV 
binding to ROS-DNA, thus suggesting the presence of oxidative lesions in these 
patients which are being recognized by the monoclonal antibodies. 
ROS-DNA was found to be a potent immunizing stimulus, inducing high 
litre anti-ROS-DNA antibodies in rats as evaluated by direct binding ELISA. 
Kidney sections of the immunized rats were tested for immune complex 
deposition by immunofluorescence. There was found to be a concentration of 
immune complexes in the glomeruli of the kidneys which was exhibited as apple 
green fluorescence. The immune complex deposition may cause kidney 
inflammation and tissue destruction. This could be correlated to acute stage of 
lupus nephritis wherein deposition of immune complexes between DNA and 
antibodies to DNA has been considered to elucidate inflammatory reaction. 
In conclusion it could be summed that native DNA modified by ROS is 
rendered immunogenic in rats and immune complex deposition in kidney could 
be detected. Also monoclonal antibodies were found to be specific towards ROS-
epitopes with special affinity for ROS-thymine and ROS-poly(dT). A similar 
observation was made when anti-DNA autoantibodies from SLE sera were 
probed for their binding with other inhibitors besides native DNA. Thereby 
suggesting that probably thymine in DNA upon modification with hydroxyl 
radical undergoes conformational changes rendering DNA immunogenic leading 
to the production of circulating antibodies cross reacting with native DNA in 
SLE. Monoclonal antibody was also found to be a good probe for assessing 
oxidative damage to the human genome in systemic lupus erythematosus. 
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In the beginning until 1944, it was generally assumed that 
chromosomal proteins carry genetic information and that DNA plays a 
secondary role. This prevailing view was decisively shattered by the 
rigorously documented finding by Oswald Avery, Colin MacLeod and 
Maclyn McCarty, that purified DNA has genetic specificity. Their 
finding was strongly reinforced eight years later in 1952 by Hershey 
and Chase. The discovery of the DNA double helix by Watson and Crick 
in 1953, revolutionized biology because it led the way to an 
understanding of gene function in molecular terms. The Watson and 
Crick DNA model known as the B-DNA helix, is the most accepted 
structure of DNA molecule in solution. An important and noteworthy 
feature of this is that it can be smoothly bent into an arc or it can be 
supercoiled with rather little change in local structure. It can also be 
kinked - that is, bent at discrete sites. X-ray diffraction studies have 
shown that various alternative conformations of DNA such as A- and 
C- DNA exist within the right handed family (Adams et al., 1981) (Table 
1) and also a triple helical form called H-DNA (Frank-Kamenetskii, 
1990) while Z-DNA is a left handed double helix, so called because the 
phosphates in the backbone are zig-zagged. This is adopted by short 
oligonucleotides that have sequences of alternating pyrimidines and 
purines. While the biological role of Z-DNA is uncertain, its mere 
existance graphically shows that DNA is a flexible and dynamic 
molecule. The reversal in handedness of DNA from B > Z transition 
is one of the most dramatic examples of DNA polymorphism 
(Pietrasanta et al., 1994). The various conformations of DNA are in 
equilibrium with each other (Dickerson et al., 1982; Kennard, 1983; Rich 
et al., 1984; Pechenaya, 1993). As the superhelical tension varies in 
TABLE - 1 
Different Conformations of Right Handed DNA 
Form Pitch Residue Conditions 
(A"X.) per turn in which formed 
A 28 11 Na-salt, 75% 
relative humidity 
B 34 10 Na-salt, 92% 
relative humidity 
C 31 9.3 Na-salt, 66% 
relative humidity 
From Adams et al., (1981) 
cell as a consequence of DNA transcription, such unusual structures 
may appear transiently and therefore may have functional 
significance. These different DNA conformations have been 
characterized in vitro while only the B- and Z- like DNA are thought to 
exist in vivo with a large majority of cell DNA in B- like conformation 
(Jaworski et al., 1987; Drew et al., 1988). Metal-ion induced and metal-
ion assisted radiations induce conversions from right handed B-DNA to 
the left handed Z-DNA conformation. The biological importance of such 
a conformational change is discussed in terms of the potential 
significance of the Z-DNA conformation in the control of the DNA 
transcription process (Trumbore et al., 1994). A-like DNA is usually 
formed when the relative humidity is below 75%, in other words 
dehydration favours the transition from B —> A form. However there is 
significant evidence that the conformation of poly(dG). poly(dC) in 
solution is A-like (Sarma et al., 1986). Also small regions of DNA are 
in an A-like conformation in vivo. Recently it has been reviewed that 
DNA in dormant spores of Bacillus species is indeed an A-like 
conformation and that A-like DNA can also form in growing cells 
(Setlow, 1992). Besides these, double helical RNA hairpins and RNA-
DNA hybrids are known to adopt the A-helix structure. Thus DNA 
molecule is highly flexible and its structure depends on interactions 
with other molecules (Travers, 1989). 
Immunogenicity of DNA 
Antigenicity of nucleic acids was recognized only much later than those 
of proteins, polysaccharides and some forms of lipids. The study of anti-DNA 
antibodies has been underway since about 1957, when DNA was 
identified as a reactant for systemic lupus erythematosus (SLE) anti-
DNA autoantibodies. An important feature that has emerged is that 
although most nucleic acids are considered immunogenic, double 
stranded DNA of the B-conformation is not (Stollar, 1986). 
Immunization with Free Nucleic Acids 
Variable results have been reported concerning attempts to 
induce antibody formation by injection of free nucleic acids or nucleic 
acids with Freund's adjuvant but without any other carrier. Haskowa et 
al. (1959) attempted to immunize rabbits with DNA of thymus or Ehrlich 
ascites tumor cells; no antibodies were detectable. Wilson et al. (1965) 
found that 36 rabbits failed to respond to calf thymus DNA. Negative 
results were also obtained on the injection of purified native or 
denatured salmon, calf thymus, phage T4 or E. coli DNA (Plescia et al., 
1964; Levine and Stollar, 1968). On the other hand, Blix et al. (1954) 
immunized rabbits intravenously with DNA from calf thymus, wheat 
germ, mycobacteria and obtained sera that reacted with the 
homologous antigens. Digestion by deoxyribonuclease destroyed 
immunogenicity. However, weak alkali or further purification steps 
which should not destroy DNA, also reduced immunogenicity. A low 
degree of cross-reactivity of DNA from various sources was seen, 
especially the finding that antisera induced by calf thymus DNA did not 
react even with beef spleen or other mammalian DNA. Another 
approach in attempts to immunize with free nucleic acids has been the 
use of animals having a genetic predisposition to the spontaneous 
production of such antibodies. Injection of denatured DNA (Lambert 
and Dixon, 1968) or of the double helical polyribonucleotide, 
poly(l).poly(C) (Carpenter et al., 1970) into NZB/NZW mice 
accelerated the spontaneous production of antibodies to DNA and 
double stranded RNA. As free bacteriophage, native or denatured DNA 
was not immunogenic (Levine and van Vunakis, 1967), it appears that 
a DNA-protein complex was the effective immunogen. 
Immunization with Nucleic Acid-Methylated Albumin Complexes 
Plescia et al. (1964) showed that when equal weights of denatured 
DNA and methylated bovine serum albumin (MBSA) were mixed, a fine 
precipitate formed and when injected into rabbits with or without an 
adjuvant, induced antibodies that reacted with free denatured DNA, but 
not with native DNA. They also showed extensive cross-reactivity with 
denatured DNA from widely differing species, though differences in the 
extent of reactivity were observed. This enhancement of the 
immunogenicity of nucleic acid could be due to two reasons. 
( i) One possibility is that MBSA protects DNA from degradation by 
nucleases (Plescia et al., 1964). 
(i i) Another reason could be the function of MBSA as a physical 
carrier allowing the delivery of the macromolecular hapten to 
appropriate cells for antibody formation and providing recognition 
sites for these cells. 
Seaman et al. (1965) showed that MBSA is also an effective carrier for 
synthetic polynucleotides including poly(A), poly(I) and poly(C). All 
three antisera cross-reacted weakly with denatured DNA from several 
species. Nahon et al. (1967) immunized rabbits with complexes of 
MBSA and double-helical poly(I).poly(C) and poly(A).poly(U). On 
immunization of rabbits with MBSA complexes of right handed poly(dG-
dC).poly(dG-dC), Lafer and Stollar (1984) and Zarling et al. (1984) 
noted the formation of antibody specific for the polymer, but did not 
react with native E. coli DNA or native denatured calf thymus DNA. It 
was thus seen that complexes of double-helical polynucleotides with 
MBSA were effective immunogens only if they differed from DNA in 
some aspects of conformation and the resulting antibodies reacted only 
with the differing structures and not with native DNA (Stollar, 1970; 
Braun and Lee, 1988), Immunization with native DNA also failed to 
induce antibodies to double stranded native DNA (Steinberg et al., 
1969; Lambert and Dixon, 1970; Thoburn et al., 1971). 
The perspective on the immunologic properties of DNA has been 
substantially revised in the past few years. There is compelling evidence that, 
bacterial DNA in contrast to mammalian DNA, can induce a variety of responses 
in both normal humans and animals (Pisetsky, 1996). Contrary to the prevailing 
dogma that anti-DNA antibodies occur only in SLE, the normal human sera 
showed significant binding to DNA from two bacterial species. Micrococcus 
lysodeikticus and Staphylococcus epidermidis and also to BK polyomavirus 
(Karounos et al., 1988; Fredriksen et al., 1993). An interesting thing is that 
antibodies to bacterial DNA in normal human sera are predominantly lgG2, 
whereas lupus anti-DNA antibodies are mainly IgGl and IgG3. However, 
following immunization with bacterial DNA, cross-reactive antibodies to 
mammalian double stranded DNA do not occur (Gilkeson et al., 1991). 
Thus, there is a clear possibility that foreign DNA can drive the 
production of anti-DNA autoantibodies in a host susceptible to SLE and 
an intriguing evidence for this is the presence of bacterial DNA 
sequences in immune complexes in lupus sera. In contrast to these 
negative findings with experimental immunization, antibodies that 
react well and even preferentially with native DNA do occur 
spontaneously in autoimmune diseases, as in human systemic lupus 
erythematosus and in hybrid mice NZB/NZW. These when immunized 
with either bacterial or BK viral DNA produce cross reactive antibodies 
to mammalian double stranded DNA (Fredriksen et al., 1994; Gilkeson 
et al., 1995). Left handed Z-DNA is an example of a helical DNA that is 
a much more potent immunogen than native B-helical DNA (Lafer et al., 
1981; Madaio et al., 1984). Chemically or physically modified DNA, or 
helical structures that differ significantly from the B-DNA helix, are 
much stronger immunogenic stimuli than native DNA and most of the 
antibodies induced by modified native DNA do not react with the 
unmodified DNA (Anderson et al., 1988). 
Reactive Oxygen Species 
The frequency with which oxygen is used in clinical medicine must not 
blind us to the fact that it has many toxic effects. Oxygen supplied at greater 
concentrations than those in normal air has long been known to damage plants, 
animals and aerobic bacteria such as E. coli (Morris, 1976; Balentine, 1982). 
This genotoxicity of oxygen and its metabolites is of fundamental interest to 
basic research in the etiology of aging and carcinogenesis (Ames, 1983; 
Strehler, 1986; Loft and Poulsen, 1996). 
It has been proposed that many of the damaging effects of oxygen could be 
attributed to the formation of oxygen radicals (Gilbert, 1981) which are chemically 
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reactive species like superoxide (Oj), hydrogen peroxide (HjOj) and hydroxy! radical 
(•OH) (Halliwell, 1987; Halliwell and Gutteridge, 1989). 
(a) Superoxide 
One electron reduction of oxygen leads to the formation of superoxide 
radical (Farhataziz and Rodgers, 1987). 
O2 + e- > 02*-
Which is formed in almost all aerobic cells (Fridovich, 1975, 1978a; 
Halliwell, 1981). One of its important source being the 'respiratory 
burst' of phagocytic cells when they contact foreign particles or 
immune complexes (Halliwell, 1982). Phagocytic cells known to produce 
O2*' include neutrophils, monocytes, macrophages and eosinophils. 
(b) Hydrogen peroxide 
It is a normal metabolite in aerobic cells, formed by the divalent 
reduction of dioxygen or by dismutation of the superoxide anion radical (O2*') 
(Tachon, 1989). 
202*- + 2H+ > H2O2 + O2 
In cellular steady state, the concentration of hydrogen peroxide is in the 
range of 10" — 10^ M (Oshino et al., 1973). However, its production can be 
increased under several pathological conditions" especially at the site of 
inflammation where the oxidative burst of the phagocytic cells occur 
(Hammers and Roos, 1985) and upon irradiation with near ultraviolet 
light or visible light (Hoffman and Meneghini, 1979) and ionizing 
radiation (Hart, 1972). 
(c) Hydroxyl radical 
This is one of the most reactive of all reactive oxygen species and attacks 
virtually any organic compound with kinetics which are close to diffusion 
limited processes (Halliwell and Gutteridge, 1986; Buxton et al., 1988). The 
chemical process of its generation can be expressed as the Haber-Weiss reaction 
(Haber and Weiss, 1934). 
H2O2 + Oj- > 'OH + OH- + O2 
This reaction is thermodynamically feasible, but kinetically very 
slow unless certain transition metals are present (Halliwell, 1978; 
McCord and Day, 1978). Iron is an excellent catalyst and through its 
mediation the above reaction can be written as a sum of two other 
r eac t ions . 
Oj- + Fe3+ > Fe2+ + O^ 
Fe2+ + H2O2 > Fe3+ + 'OH + OH" 
O2- + H2O2 > 'OH +0H- +O2 
This reaction is referred to as the Fenton reaction (Fenton, 1894). 
Other transition metals like copper and cobalt can also form the 
reaction species (Moorhouse et al., 1985; Goldstein and Czapski, 1986; 
Nackerdien et al., 1991). 
Cu+ + H2O2 > Cu2+ + 'OH + OH-
It is however, not clear whether reaction with copper can occur in 
the cell since it has been shown that free copper ions are not available 
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and protein bound copper ions are unable to catalyze the formation of 
•OH (Rowley and Halliwell, 1983). It has been shown that Cu^^ and HjOj 
or Fe-'^ and H2O2 - catalyzed reactions require the presence of a 
reducing agent such as ascorbate (Stoewe and Prutz, 1987) or NADPH 
(Imlay and Linn, 1988). Increased cellular production of reactive 
oxygen species (ROS) has also been observed upon exposure to visible 
and ultraviolet light (Hoffmann and Meneghini, 1979) and ionizing 
radiation (Hart, 1972). Thus free radicals can be generated in living 
cells by indigenous sources (eg. oxidant enzymes, phagocytic cells) 
and also by exogenous sources (eg. redox - cycling drugs, ionizing 
r ad i a t i on ) . 
ROS and DNA Damage 
Oxidative DNA damages constitute probably the most varied class of DNA 
damages. Nearly 100 different free radical damages have been identified 
(Dizdaroglu, 1992). Figure 1 shows the possible pathways for the induction of 
DNA damage by various reactive oxygen species. While cellular antioxidant 
defenses exist, these are not perfect and the number of oxidative hits per cell in 
humans has been estimated at 10,000 per day. (Burdon et al., 1996). 
Endogenously generated oxidants that could lead to cellular DNA damage 
include superoxide radicals and hydrogen peroxide. There have been many 
reports to indicate that the human genome is potentially vulnerable to 
damage by HjOj (Meneghini and Martins, 1993). In addition, 
superoxide is normally generated intracellularly, from single electron 
transfer to oxygen but is probably converted to membrane permeable 
H2O2 by Mn-superoxide dismutase located in mitochondria. It has been 
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Figure 1. Possible pathways for the induction of DNA damage by 
various reactive oxygen species. 
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suggested that H2O2 mediated DNA damage occurs at the site where the 
reduced metal is bound to the DNA (Czapski, 1984). The cytotoxic 
action of HjOj is via the hydroxyl radical which may attack DNA at 
either the sugar or the base (Hutchinson, 1985), ultimately causing 
DNA strand breaks. The mechanism of single strand breaks involves 
addition of 'OH to C = C of the base or abstraction of hydrogen atoms 
from the various positions of sugar moiety (Schulte-Frohlinde and von 
Sonntag, 1985). Mitochondrial DNA (mtDNA) have been found to be 
especially vulnerable to attack by ROS (Driggers et al., 1996) since: 
(a) these organelles consume —90% of the body's oxygen and ~ 1-2% of 
the oxygen metabolized is converted to superoxide (Richter, 1992); (b) 
the mtDNA is in close proximity to the inner mitochondrial membrane 
where the electron transport chain generates ROS and (c) the DNA of 
mitochondria is not associated with protective histones. 
(a) Base damages 
The major thymine oxidation product formed from the free radical attack 
on DNA is "thymine glycol" consisting of four isomers of 5,6-dihydroxy - 5,6-
dihydrothymine. Thymine glycol undergoes alkali - catalyzed decomposition to 
from various fragmentation products, ultimately to yield urea residues N-linked 
to deoxyribose (Demple and Harrison, 1994). These glycols can be generated 
by 'OH, ionizing radiations or ultraviolet radiations, particularly those 
induced by UV-C (190-280nm) cause photo-lesions in DNA and one type 
of damage has been shown to be the formation of pyrimidine 
cyclobutane dimer (Sage, 1993) and particularly susceptible is 
thymine. A number of modified bases have been isolated from 
chromatin of 7-irradiated human cells. These are cytosine glycol. 
13 
thymine glycol, 8-hydroxyadenine, 2-hydroxyadenine and 8-
hydroxyguanine (Nackerdien et al.,\992). 
Formation of thymine radicals in the reaction with OH radical is shown 
below: 
O'^N^^H O'^N'-^H O'^N^'^" 
H H H 
J _ > 5 - T - O H + 6 - T ' - 0 H + T > H ) 
(56«/o) (35Vo) (9«/o) 
Other major oxidized DNA base derivatives that have thus far been 
identified as a result of ROS attack on DNA are 5-hydroxymethyi-2'-
deoxyuridine (HMdU), thymidine glycol (dTG), 7,8-dihydro-8-oxoadenine (8-
oxo-dA) (Malins and Haimanot, 1990; Kamiya et al., 1995a) and 8-oxo-2'-
> 
deoxyguanosine (8-oxo-dG) (Teebor et al., 1984). The measurement of 8-
hydroxydeoxyguanosine has become increasingly popular as a marker 
of oxidative damage to cellular DNA (Lunec et al., 1994). 
(b) Deoxyribose damages 
The phosphodiester backbone of DNA is readily attacked by free radicals. 
The attraction by this polyanion, of metals such as Fe^"^ or Cu*"^  may 
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also target localized formation of •OH by HjOj (Imlay and Linn, 1988). 
The resulting damages can displace bases, oxidize deoxyribose and 
fragment the sugar. The resulting strand breaks are the hallmarks of 
oxidative damaging agents such as X-rays or hydrogen peroxide, and 
all of these damages cause a complete loss of genetic information in 
the affected strand. Double strand breaks are characteristic of ionizing 
radiations (von Sonntag, 1987). 
First Line of Defence Against ROS 
Antioxidants and hydroxyl radical scavengers 
The accumulation of reactive oxygen species (ROS) would be deleterious 
to the cell and has to be prevented. Living systems have evolved antioxidant 
defences to protect against free radicals. Superoxide dismutase (SOD) catalyses 
the inactivation of 0*2 (Fridovich, 1978b; Halliwell and Gutteridge, 1986). 
SOD 
2H+ + 202*- > H2O2 + O2 
whereas catalase and peroxidase are that of H2O2 
Catalase 
2H2O2 > 2H2O + O2 
Glutathione 
H2O2 + 2GSH > G-S-S-G + 2H2O 
peroxidase 
Other antioxidants such as ascorbic acid and vitamin E may also 
play a critical role against oxidative damage (Herbaczynska-Cedro et 
al., 1994). Besides these, P-carotene (Ames, 1983), the tocopherols 
(Porter et al., 1983) and uric acid (Ames et al., 1981) are also effective 
antioxidants. Lidocaine is a local anaesthetic and has been found to 
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be a potent scavenger of hydroxyl radical and singlet oxygen (Das and 
Misra, 1992). Recently, potent antioxidant activities of pteridines, 
particularly the reduced form of neopterin have been demonstrated 
(Icho et al., 1993), which have been substantiated by Weiss et al. 
(1993). Another useful biological antioxidant that has gained 
recognition is thioctic acid (or lipoic acid) and its reduced form 
dihydrolipoic acid, particularly in their ability to inhibit lipid 
peroxidation (Suzuki et al., 1991). Taprostene, a prostacyclin analogue 
has been found to be an effective scavenger of hydroxyl radical 
(Arroyo et al., 1994). However, excessive antioxidant action can 
adversely affect key physiological processes. At the Food and Drug 
Administration conference (U.S.A.) on antioxidant vitamins and cancer 
and cardiovascular disease (1993), it was unanimously agreed that 
vitamins C,E and p-carotene are mischaracterized by describing them 
solely as "antioxidants". They are in fact redox agents i.e. antioxidants 
in some circumstances (often so in the physiologic quantities found in 
food) and prooxidant in other circumstances (often so in the 
pharmacologic quantities found in supplements). Hence it is a myth 
that a supplement is a pure antioxidant. However, dietary antioxidants 
present in fruits and vegetables are thought to decrease free radical 
attack on DNA (Duthie et al., 1996). 
Second Line of Defence 
DNA repair 
An immediate response to DNA damage is DNA repair. Considering the 
appreciable specificity of the DNA repair systems and the relatively 
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large spectrum of DNA lesions produced by the oxygen species, 
several repair pathways are likely to be elicited when cells are 
exposed to such species (Sage, 1993). In mammalian cells, these 
repair pathways are poorly characterized and despite the abundant 
information flowing from the facile combination of biochemical and 
genetic approaches in E. coli, the function of mammalian counterparts 
of the microbial enzymes is only hypothesized or extrapolated from 
microbial models. The nucleotide excision repair system of E. coli 
UvrABC although not pivotal for handling oxidative damage in contrast 
to its crucial role in the repair of structurally distorting lesions such 
as pyrimidine photodimers and son.e carcinogen adducts (Sancar and 
Tang, 1993), nevertheless, acts as a secondary defence against 
oxidative damages. On the other hand, recombination mechanisms can 
in principle repair any DNA lesion, provided that an intact copy of the 
affected region resides in the same cell (West, 1992). Recombination 
is likely to be crucial for at least two classes of oxidative damages: 
interstrand crosslinks and double-strand breaks. 
Besides these repair systems, certain enzymes such as DNA 
glycosylases are important in initiating repair by hydrolyzing the 
base-sugar (N-C glycosylic) bond of modified or incorrect base to 
generate abasic (AP) sites (Sancar and Sancar, 1988). Endonuclease 
III of E. coli is a thymine glycol glycosylase that specifically cleaves 
duplex DNA damaged by X-rays (Strniste and Wallace, 1975), UV light 
(Radman, 1976), osmium tetroxide, or acidic pH (Gates and Linn, 1977). 
Thymine glycol and dihydrothymine were the first identified substrates 
for the endonuclease III glycosylase (Demple and Linn, 1980). 
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Possible counterparts to E. coli endonuclease III have been found in other 
organisms. Some other glycosylases include formamidopyrimidine glycosylase, 
hypoxanthine - DNA glycosylase, 5-hydroxymethyl uracil and 5-
hydroxymethylcytosine DNA glycosylases. It has been suggested that the last 
two glycosylases exist to maintain 5-methylcytosine in the DNA of vertebrate 
cells in the face of free radical damage (Cannon-Carlson et al., 1989). The 
repair enzymes identified so far can be used as gentle probes for a more 
complete understanding of oxidative damage to DNA under physiological 
conditions. It is when the defence at any level is shattered that the ROS may 
harm DNA and disease may manifest. 
Autoimmunity 
Autoimmune diseases are caused by failure to distinguish between host 
and foreign antigens. It was proposed by Niels Jerne (1955) that antibodies are 
not formed on an antigen template, but are preformed in myriad diversity, 
awaiting selection by a complementary antigen. Macfarlane Burnet (1959a) 
proposed that antibodies are produced by lymphocytes and that each lymphocyte 
makes only one type of antibody. A lymphocyte clone is a subset of lymphocytes 
with identical receptors for antigen. Each clone comprises millions of 
lymphocytes and an individual has millions of different clones. Normally, in 
foetus, clones reactive with host antigens are destroyed as they rise, so that we 
are all born free of autoimmune disease (Adams, 1996). However, later 
on in life random somatic mutations may arise and activate a clone 
that can react with one of our self-antigens, Burnet (1959 b, c) termed 
such self-antigen-reactive clones "forbidden clones" and proposed that 
they are the cause of the various autoimmune diseases. Thus, 
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autoimmunity can be defined by the presence of autoantibodies and/or 
T cells which react against self antigens (Druet, 1992). The dogma that 
the internal milieu of cells is immunologically privileged and cannot be 
reached by autoantibodies was first challenged when IgG anti-
ribonucleoprotein (RNP) and anti-DNA were shown to enter cells, reach their 
intranuclear antigen, modify cell functions and cause cell death (Alarcon-
Segovia et al., 1982). Recent data have indicated that the phenomenon is 
widespread and is involved in potential immune regulation and prevention as 
well as pathogenesis of autoimmunity (Alarcon-Segovia et al., 1996). 
Role of MHC in Autoimmunity 
The involvement of MHC molecules and T cells in the development of 
autoimmune disease might be possible by influencing selection of T cell 
receptors in the thymus. A particular MHC molecule might delete T cells that 
normally suppress autoimmune responses in the periphery, or alternatively, 
might allow autoimmune T cell receptors to escape thymic deletion (Mellins, 
1992). In addition to thymic selection, other mechanisms involved in the 
maintenance of tolerance to self proteins may be disrupted in autoimmune 
disease. One scenario to explain this has been proposed by Bottozzo et al. 
(1983). According to them, an environmental trigger, either a microbe or a toxin 
leads to tissue damage, which releases antigen from sites that were previously 
sequestered from the immune system. In addition, tissue damage stimulates an 
inflammatory response including release of lymphokines such as 
interferon-Y which induce expression of class II molecules on cells that 
do not otherwise express class II molecules, enabling these cells to 
become antigen presenting cells. Alternatively, increased levels of 
class II molecules are induced on resident macrophages, enhancing 
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their antigen presenting capacities. This cascade of events leads to 
presentation of self antigens which are normally hidden from the 
immune system. 
Thymic selection and antigen presentation may sometimes 
operate simultaneously to mediate disease susceptibility. MHC 
molecules may also confer disease by another mechanism, referred to 
as molecular mimicry. In this, the structural similarity between MHC 
molecules and environmental pathogens leads to autoimmune disease 
in one of the two ways. Shared residues inhibit the normal response 
against a pathogen which causes disease, or alternatively an immune 
response to the pathogen leads to an attack on host cells which 
express cross-reactive MHC proteins. Support for this molecular 
mimicry hypothesis comes from finding sequence homology between 
various MHC alleles and certain pathogens (Mellins, 1992). 
Etiology of Autoimmune Diseases 
No single theory or mechanism can adequately explain all features of 
autoimmune diseases. Perhaps the best approach, as suggested by Shoenfeld and 
Isenberg (1989), is to consider the wide spectrum of autoimmune diseases as the 
"mosaic" of autoimmunity with its many pieces: genetic, hormonal, 
immunological and environmental, leading to diverse diseases. The old 
"forbidden clone theory" has undergone several modifications, and more 
recently been abandoned in favor of the multifactorial considerations 
(Theofilopoulos and Dixon, 1985; Huang et al., 1988; Deodhar, 1992). 
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(a) Role of genetic factors 
Autoimmune diseases in general show a highly significant 
familial predisposition. Relatives of patients with a particular 
autoimmune disease are known to be at high risk for developing the 
same disease and the relevant autoantibodies are known to occur in a 
much higher frequency among patients' relatives than in general 
population (Hochberg, 1987; Arnett, 1992), The involvement of genetic 
factors has been linked to the human lymphocyte antigen (HLA) system 
particularly the HLA-DR sublocus. The HLA genes function as 
secondary genes to allow expression of specific autoantibody or the respective 
disease state (Bias et al., 1986). 
(b) T-helper/ T- suppressor cell imbalance 
The immune system is controlled mainly by the regulatory influence of T-
lymphocyte subsets: T-helper and T-suppressor cells. In normal individuals, the 
ratio of T-helper to T-suppressor cells in peripheral blood tends to be 
approximately 2:1, whereas in almost all of the autoimmune diseases studied so 
far, this ratio is considerably greater, often approaching 10 or 15:1, particularly 
during the acute or active phase of the disease (Morimoto et al., 1987; 
Shivakumar et al., 1989). In most cases there is a significant decrease in T-
suppressor cells number and activity and this accounts for the increased T-
helper/ T-suppressor ratio. 
(c) Hormonal factors 
It is well known that autoimmune diseases occur far more 
commonly in females than they do in males, with the ratio of female to 
male involvement often reaching 10:1 or greater in certain diseases 
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(Talal, 1979). There is evidence to support the hypothesis that sex 
related factors are involved in the pathogenesis of SLE (Talal, 1989; 
Carlsten et al., 1990; Counihan et al., 1991; Lahita, 1992). It has been 
reported that testosterone and thymic hormones enhance CD8+ T cell 
receptor function (Lahita and Kunkel, 1984), whereas estrogen may 
suppress this function (Talal and Ahmad, 1987). Also, female relatives 
of patients with certain autoimmune diseases have been reported to 
demonstrate a significant prevalence of autoantibodies and suppressor T cell 
defects (Miller and Schwartz, 1982). 
(d) Polyclonal B-cell activation 
Polyclonal B-cell activation may be one possible mechanism responsible 
for the over-activation of B-cells and production of autoantibodies in certain 
autoimmune diseases, particularly SLE (Dziarski, 1988; Klinman et al., 1990; 
Steinberg, 1992). B-cell hyper-responsiveness and spontaneous polyclonal 
activation are invariably present in both SLE patients and animal models of 
SLE. The sequence of events is believed to be as follows: in autoimmune prone 
individuals B-cells are hyper-responsive to polyclonal activators and undergo 
initial activation, followed by expansion including that of the autoreactive 
clones under the influence of exogenous or endogenous polyclonal activators 
(Theofilopoulos, 1993; 1995). 
Table 2 shows the various autoimmune diseases and their respective 
a u t o a n t i b o d i e s . 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a multifactorial 
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TABLE 2 
Autoimmune Diseases and Their Respective Autoantibodies 
Disease Autoantibodies directed against 
SLE and related diseases 
Systemic lupus erythematosus 
(SLE) 
Scleroderma (PSS) 
Sjogren^s syndrome 
Mixed connective tissue disease 
Rheumatoid arthritis 
Other autoimmune diseases 
Autoimmune thyroid diseases 
Addison's disease 
Pernicious anemia 
Inflammatory bowel diseases 
Chronic active hepatitis 
Primary biliary cirrhosis 
Myasthenia gravis 
Goodpasture's syndrome 
Pemphigus vulgaris 
Bui ous pemphigoid 
Autoimmune hemolytic anemia 
Multiple sclerosis and related 
demyelinating diseases 
Diabetes Type 1 
Wegener's granulomatosis and 
other vasculitides 
Nuclear antigens, DNA, Sm, 
Cardiolipin 
Nuclear antigens, Scl-1, Scl-70 
Nuclear antigens SS-A, SS-B 
Extractable nuclear antigen (RNP) 
Fc portion of IgG (rheumatoid 
factor), nuclear antigens 
Thyroglobulin, microsomal 
antigen, TSI 
Adrenal cortical cell antigen 
Intrinsic factor, parietal cell 
antigen 
Colonic mucosal antigen 
Smooth muscle antigen 
Mitochondrial antigen 
Acetylcholine receptor 
Glomerular basement membrane 
Epidermal intercellular substance 
Skin basement membrane 
Red cell membrane antigens 
Myelin basic protein antigen 
Islet cell antigen 
(also cytotoxic T cells) 
Serine protease and 
myeloperoxidase 
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autoimmune disease of unknown etiology (Isenberg and Shoenfeld, 
1987) and its characteristic features include (1) polyclonal B cell 
activation, (2) overexpression of the immune stimulatory cytokine 
interleukin-6 (IL-6), (3) defective tolerance of self antigens and (4) 
production of anti-DNA antibodies (Tan et al., 1980). Figure 2 shows the 
genetic and environmental factors contributing to SLE. Bacterial 
infection has been suspected as a triggering factor for lupus. This 
could be due to the CpG motifs in bacterial DNA which induce a variety 
of immune effects such as polyclonal activation of murine and human 
B cells, IL-6 secretion and resistance to apoptosis thereby potentially 
allowing survival of autoreactive cells (Krieg, 1995). Active lupus is 
classically associated with the pathogenic production of IgG anti-DNA 
antibodies (Feldman et al., 1982). These anti-DNA antibodies found in 
the sera of patients with SLE are of diverse antigenic specificities 
(Pollard et al., 1986; Ali et al., 1991), which include components of DNA, 
its different conformations including modified structures (Hasan et al., 
1991; Alam and Ali, 1992). This diverse recognition of antigens by 
lupus B cells have led investigators to postulate that the expressed 
repertoire must be cross reactive (Klinman et al., 1994). Although 
antibodies to double stranded DNA are the hallmark of SLE and are 
thought to bind DNA and form immune complexes, it has also been 
suggested that anti-dsDNA antibodies may cross react with non nucleic 
acid antigens such as proteins (Raz et al., 1993), A and D snRNP 
polypeptides (Reichlin et al., 1994). Recent studies suggest that some 
anti-DNA antibodies in SLE may actually be antibodies to specific 
proteins and that binding to dsDNA is a nonspecific cross-reactive 
event (Zack et al., 1995). Other findings indicate that the nucleosome 
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as a multimolecular complex or its non-DNA component, i.e. histone, 
may be viewed as relevant target autoantigens in SLE (Jacob and 
Viard, 1992). Since anti-histone reactivity reflects, at least partly, the 
presence of anti-DNA antibodies complexed to DNA, which could bind 
to cell-membrane determinants, and is associated with disease clinical 
activity, it is suggested that this mechanism can contribute to explain 
the pathogenicity of anti-DNA antibodies (Viard et al., 1992). 
Another characteristic feature of systemic lupus erythematosus is 
its high prevalence among yourg women (Kotzin and O' Dell, 1994) 
which suggests a role for sex hormones in the development of the 
disease, with estrogens exerting an enhancing effect and androgens, a 
protective influence. It has been suggested that estradiol in 
conjugation with BSA and DNA could form a possible antigenic trigger 
for SLE, which results in the production of autoantibodies highly 
specific towards the immunogen (Moinuddin and Ali, 1994). However, 
quantitatively, the level of anti-estradiol antibodies has been found to 
be at least an order of magnitude lower than the anti-DNA antibodies 
characteristic of this disease (Counihan et al., 1991). 
The existence of several strains of mice having high levels of 
antinuclear antibodies and a lupus like renal disease has greatly 
facilitated investigation into the pathogenesis of SLE. These strains 
include (NZB X NZW)F1, (NZB X SWR)F1, BXSB and MRL-lpr/lpr. It has 
been found that (NZBXNZW)Fl mice, like humans with SLE develop 
autoantibodies to a number of nuclear components including single and 
double-stranded DNA and histones. Autoantibodies against dsDNA 
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appear to be the most pathogenic and almost 90% of female mice test positive 
for anti-dsDNA antibodies (Drake et al., 1995). In contrast, repeated attempts 
to specifically induce anti-DNA antibody similar to that produced in autoimmune 
mice have met with limited success (Stollar, 1989), although antibodies that 
react with B-conformation (native) of DNA are found in patients of SLE, In 
light of this, it has been suggested that in SLE and other chronic inflammatory 
diseases, the phagocytic cells release oxygen species into the extracellular 
environment. These being highly reactive penetrate cellular membranes and 
react with nuclear DNA (Joenje, 1989) causing damage (Schneider et al., 1989). 
Such ROS-damage to DNA induces antigenic changes in it (Blount et al., 1989). 
Also, naturally occurring anti-DNA antibodies show increased binding to DNA 
modified with ROS when compared with native antigen (Blount et al., 1990; Ara 
and All, 1992). The antibodies induced by ROS-DNA were found to recognize 
native B, A and allied conformations of DNA (Ara and Ali, 1993). 
Clinical Manifestations of SLE 
SLE is heterogeneous in nature and the clinical course of patients with 
SLE is extremely variable. While some patients have mild forms of disease with 
spontaneous remissions and regressions, others demonstrate low levels of skin 
and joint involvement including arthritis, vasculitis and skin rashes. 
Still other patients follow a more relentless course, progressing to end 
organ damage such as renal failure frequently with multisystem 
involvement. Patients of SLE also exhibit high lipid profiles, which are 
known to arise from renal involvement and a nephrotic state (Attman 
and Alaupovic, 1990; Appel, 1991). Other contributory factors may be the use 
of drugs, in particular steroids and antihypertensive agents. Neurological 
involvement is also common in SLE inflicted individuals (Adelman et al., 
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1986). More than 60% of patients have CNS manifestations and 30-40% have 
neuromuscular abnormalities (Omdal et al., 1989). This might be due to SLE 
involvement of muscles and nerves or psychological factors like depression, or 
disease complications or a concomitant disease. It has been observed that 
patients with SLE, who have as part of their disease persistent rheumatoid-like 
arthritis are less likely to be hypertensive than other patients with SLE and this 
protection is conferred by a higher frequency of the DR4 allele (Kaplan et al., 
1992). A further abnormality of SLE is the presence of circulating immune 
complexes (Bruneau and Benveniste, 1979). Formation of the altered base, 8-
oxo-dG (8-hydroxydeoxyguanosine) has been shown to be a very sensitive 
marker of ROS-induced damage and patients with SLE have undetectable levels 
of urinary 8-oxo-dG (Lunec et al., 1994). There has also been found to be an 
increased risk of cancer, especially lymphomas in patients with SLE (Pettersson 
et al., 1992). 
Implications for Therapy 
Human SLE is likely to have multiple etiologies, different in 
different individuals. Thus it seems unlikely that the specific etiology 
of the lupus syndrome will be worked out for each individual patient in 
the immediate future. If lupus is due to a loss of self tolerance, it may 
be possible to design a more general therapy to restore self-tolerance 
without the requirement for correction of the specific defect (Steinberg, 1994). 
Gene therapy, another approach to curing of lupus has been performed 
successfully in mice. Meanwhile medication includes nonsteroidal anti-
inflammatory drugs for mild form of the disease while high doses of 
corticosteroids and immunosuppressive drugs are needed for chronic SLE 
patients (Blank et al., 1992). Provided that kidneys are not yet irreversibly 
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damaged, the use of human soluble or chimeric receptors (constant part of 
human Ig heavy chain linked to the human soluble IFN-y receptor)(Kurschner et 
al., 1992 a, b) is an attractive perspective in the treatment of autoimmune 
glomerulonephritis in human SLE (Ozmen et al., 1995). Survival of patients 
with systemic lupus erythematosus in developed countries has improved 
considerably over the last 2 decades, but in India it appears that for a significant 
change in survival, an overall improvement m the standard of medical care is required. 
(Kumar et al.. 1992). 
Role of ROS in Other Diseases 
The role of oxygen free radicals has been implicated in a variety of 
pathophysiological conditions including cancer, aging, diabetes, heart disease 
and various neurological disorders (Halliwell and Gutteridge, 1985; Knight, 
1995). There is reasonable evidence to suggest a possible role of free radicals 
induced DNA damage in the development of carcinogenesis (Olinski et 
al., 1992; Kasprzak, 1995). The development of neoplastic cells from 
normal ones proceeds by multiple steps involving initiation, promotion 
and progression. Initiation refers to the irreversible cellular changes 
in genomic components by free radicals. Furthermore, there is 
evidence to suggest that tumor cells have abnormal levels and activities of 
antioxidant enzymes such as superoxide dismutase or catalase which may cause 
accumulation of O*^ and HjOj with subsequent OH* induced damage to DNA, 
resulting in greater amounts of modified DNA bases in tumor cells than in 
normal cells (Olinski et al., 1992). 
Reactive oxygen species (ROS) play an important role in the killing of 
many microorganisms by mononuclear phagocytes and neutrophils (Segal, 1989). 
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Although data are discrepant, several studies have suggested that the generation 
of reactive oxygen intermediates (ROI) is impaired in mononuclear phagocytes 
and possibly also in neutrophils from HIV-infected individuals. This could lead 
to deficient killing of intracellular microorganisms, predisposing the HIV-
infected patients to various opportunistic infections, thus suggesting the possible 
role of ROI in the immunopathogenesis of HIV infection (Muller, 1992). 
Monoclonal Antibodies to DNA 
In 1975, Kohler and Milstein first reported that homogeneous monoclonal 
antibodies with a selected specificity could be generated by fusing antibody-
producing cells sensitized against a defined antigen with a myeloma cell line. 
The technique was rapidly developed to obtain high affinity antibodies 
with a high level of accuracy. Monoclonal antibodies have proven to be 
important tools in tlie analysis of the role of anti-DNA antibody in SLE, 
providing valuable insights into interactions of antibodies with DNA 
and the possible mechanisms stimulating anti-DNA responses (Emlen 
et al., 1986). Anti-DNA antibodies have been shown to be markedly 
heterogeneous with respect to binding to DNA (Isenberg et al., 1994) and 
polyspecificity has emerged as one of the most intriguing findings of monoclonal 
antibodies. A recurring finding has been that many monoclonal autoantibodies 
cross react with several synthetic polynucleotides (Kardost et al., 1982; 
Shoenfeld et al., 1983). However, immunization with synthetic polynucleotides 
usually leads to a specific antibody that does not show this degree of cross 
reactivity. Another recurring finding is the prominence of certain 
polynucleotides, particularly poly(dT) and poIy(dG) or poly(I) as preferred 
reactants for both murine and human hybridoma products (Arnott et al., 1974). 
The cross reactivity of anti-DNA antibodies could result from their binding to 
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antigens which are structurally distinct yet share particular epitopes (Carroll et 
al., 1985; Schwartz and Stollar, 1985). The idiotype B3-Id is the first to be 
derived from a human monoclonal anti-DNA antibody of the IgG class 
(Ehrenstein et al., 1994). In order to determine the capacity of the 
autoantibodies to penetrate cells and induce functional perturbations in vivo, 
monoclonal anti-DNA antibodies derived from MRL-lpr/lpr and (NZBXSWR) Fl 
mice were administered to normal mice and examined for morphologic and 
functional abnormalities (Vlahakos et al., 1992). It was found that a subset of 
autoantibodies may penetrate cells in vivo to influence normal cellular and 
nuclear function. Other studies have revealed that certain IgM class anti-DNA 
antibodies in human systemic lupus erythematosus may arise by antigen 
stimulation and not simply by polyclonal B-cell activation (Suenaga and Abdou, 
1992). Various results obtained in experimental models have raised hopes by 
showing that some of the monoclonal antibodies can induce highly selective 
immunosuppression and tolerance. Use of short courses of. anti-CD3 and anti-
CD4 antibodies has been found to induce long-term remission of autoimmune 
diseases. Such tolerance ind'iction has not been achieved in humans with 
conventional immunosuppressive therapy and hence the efficacy of MAbs in 
autoimmune diseases. (Bach et al., 1993). 
Earlier studies conducted in our laboratory have modified cellular DNA 
and DNA fragments of 300bp with UV light in the presence of hydrogen 
peroxide (Ara et al., 1992; Ara and Ali, 1993). Single strand breaks, decrease 
in Tm and modification of bases were some of the major changes observed in 
DNA. Polyclonal antibodies induced in experimental animals against the 
modified DNA were immunogen specific. They also recognized native B, A- and 
allied conformations thus exhibiting polyspecificity. It was also observed that 
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naturally occurring anti-DNA autoantibodies from systemic lupus erythematosus 
(SLE) sera recognized modified DNA. 
Objectives of the Present Study 
The basic question of why anti-DNA autoantibodies are formed in SLE is 
yet to be answered with conviction. It is not sure whether some form of DNA, 
such as a product of viral infection or a fragment of chromatin or chemically 
modified DNA serves as immunogen. In the present work, calf thymus DNA was 
modified with hydrogen peroxide in the presence of UV light of 254nm and the 
chemical alterations to DNA mediated by hydroxyl radical under these 
conditions were detected by UV spectroscopy, thermal denaturation studies, 
sedimentation in alkaline sucrose density gradient and nuclease SI sensitivity. 
In addition, ion exchange chromatography on DEAE Sephadex A-25 column was 
used to reveal the modified base products in DNA. The ROS-DNA was used to 
induce antibodies in rats which were tested for immune complex deposition in 
the kidney glomeruli by immunofluorescence. Furthermore, monoclonal antib-
odies made against 400 bp ROS-DNA were characterized for their fine antigenic 
specificity. In addition, two DNA bases one purine and one pyrimidine ie. 
adenine and thymine and their respective homopolymers poly(dA) and poly(dT) 
were modified with ROS and the extensive changes induced in them were 
determined by UV spectroscopic studies. These modified bases and polymers, 
as well as native and ROS-DNA were subsequently used to detect their binding 
to human anti-DNA autoantibodies in the sera of SLE patients by various 
techniques to find out the possible role of ROS-modified epitopes in the etiology 
of SLE. In order to strengthen the finding that ROS-modified epitopes are being 
preferentially recognized by SLE autoantibodies, the monoclonal antibody was used 
as a probe to detect oxidative damage to DNA isolated from SLE patients. 

32 
MATERIALS 
Calf thymus DNA, nuclease SI (Aspergillus oryzae), bovine serum 
albumin, agarose, anti-human, mouse and rat-IgG-alkaline phosphatase and HRP 
conjugates, thymine, trinitrobenzene sulphonic acid, ethidium bromide, Freund's 
complete and incomplete adjuvants, standard protein markers, o-
phenylenediamine(OPD), Tween-20, Ficoll histopaque (1077), anti-rat-IgG-
FITC, Coomassie Brilliant Blue R250, sodium dodecyl sulphate, methylated 
bovine serum albumin and anti-mouse-lgG and IgM sub classes were purchased 
from Sigma Chemical Company, U.S.A. Hydrogen peroxide, EDTA (disodium 
salt), chloroform and phenol were from Qualigens Fine Chemicals, India. 
Synthetic polynucleotides. Protein G and A Sepharose CL-4B, DEAE-Sephadex 
A-25 and Ficoll 400 were obtained from Pharmacia Fine Chemicals, Sweden. 
Adenine was from Merck, Germany, while polystyrene flat bottom ELISA plates 
(96 wells) were procured from Nunc, Denmark. Para-nitrophenyl phosphate and 
Folin-Ciocalteu reagent were obtained from Centre for Biochemical Technology, 
New Delhi. Acrylamide, ammonium persulphate, bisacrylamide, N, N, N' , N' , 
tetraethyl methylene diamine (TEMED) and nitrocellulose membrane were from 
Bio-Rad Laboratories, U.S.A. All other chemicals were of highest analytical 
grade available. 
E q u i p m e n t 
Shimadzu UV-240 spectrophotometer equipped with thermal programmer 
and controller unit, ELISA microplate reader MR-600 (Dynatech, U.S.A.), 
ELICO pH meter model Ll-IOT, ultraviolet lamp (Vilber Lourmat, France), 
agarose gel electrophoresis apparatus GNA - 100 (Pharmacia, Sweden), 
polyacrylamide gel electrophoresis assembly (Bio-Rad, U.S.A.), Beckman 
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ultracentrifuge and fluorescent microscope (Nikon, Japan) were the major 
equipments used in this study. 
Collection of Sera 
SLE sera were obtained from patients showing high titer anti-DNA 
antibodies and fulfilled the American College of Rheumatology criteria for the 
diagnosis of SLE (Arnett et al., 1988). Complements were inactivated by 
heating serum samples at 56°C for 30 min before use. 
METHODS 
Purification of Calf Thymus DNA 
Highly polymerized calf thymus DNA was purified free of proteins, RNA 
and single stranded regions as described by Ali et al. (1985). The DNA (2 mg/ 
ml) in O.lx SSC buffer (15 mM sodium citrate, 150 mM sodium chloride, pH 
7.3) was extracted with a mixture of chloroform-isoamyl alcohol (24:1) in a 
stoppered measuring cylinder for one hr. DNA in aqueous layer was separated 
from organic layer and the extraction process was repeated. DNA was 
precipitated with two volumes of cold distilled ethanol, collected on a glass rod 
and dissolved in 30 mM acetate buffer, pH 5.0 containing 30 mM zinc chloride. 
Subsequent treatment with nuclease SI (200 units/mg DNA) at 37°C for 30 min 
removed the single stranded regions. After incubation the reaction was stopped 
by the addition of one-tenth volume of 200 mM EDTA, pH 8.0. The extraction 
procedure was repeated as before and final preparation of DNA was dissolved 
in PBS (10 mM sodium phosphate, 150 mM NaCl, pH 7.4) 
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Determination of DNA Concentration 
The concentration of DNA was determined by the method of Burton 
(1956). 
(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. 
Approximately 0.5 g of activated animal charcoal was added and filtered 
through Whatman No. 1 filter paper. The filtrate was kept overnight at 4°C. 
The recrystallized material was filtered and dried at room temperature. 
(b) Preparation of diphenylamine reagent 
Recrystallized diphenylamine (750 mg) was dissolved in 50 ml glacial 
acetic acid containing 0.75 ml concentrated sulphuric acid. 
(c) Procedure 
One ml of 1 N perchloric acid was added to 1 ml of DNA sample and 
incubated in a thermostat water bath at 70°C for 15 min. One hundred microlitre 
of 5.43 mM acetaldehyde was added followed by 2 ml of freshly prepared 
diphenylamine reagent. The tubes were kept at room temperature for 16-20 hr 
and absorbance recorded at 600 nm. The DNA concentration in unknown 
samples was determined using calf thymus DNA as standard (Fig. 3). 
Determination of Protein Concentration 
Protein was estimated by the method of Lowry et al. (1951). This method 
utilizes alkali (to keep the pH high), Cu^ "*^  ions (to chelate protein) and tartarate 
(to keep the Cu^ "^  ions in solution at high pH) 
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Fig.3. Standard plot for the colorimetric estimation of DNA. 
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(a) Folin - Ciocalteu reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate in 100 mM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared freshly before use by mixing 
components (i) and (ii) in the ratio of 50:1. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent. 
The samples were allowed to stand at room temperature for 10 min. Working 
Folin-Ciocalteu reagent (1 ml) was added to the tubes, mixed and left for 30 min at 
room temperature. The protein concentration in unknown sample was evaluated from a 
standard plot constructed by using varying concentrations of bovine serum albumin 
(Fig.4). 
Modification of DNA 
An aqueous solution of DNA (0.15 mM bp) was irradiated under 254 nm 
UV light in the presence of hydrogen peroxide in a molar ratio of 1:100 for 30 
min at room temperature. Excess hydrogen peroxide was removed by extensive 
dialysis against PBS (pH 7.4). Purified DNA samples exposed to hydrogen 
peroxide or UV light alone were the corresponding controls. 
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Standard plot for the colorimetric estimation of protein. 
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Irradiation of DNA Bases and Polymers 
Adenine (7.4 mM) and thymine (3.97 mM) in PBS, pH 7.4 were irradiated 
with 254 nm light for 30 min at room temperature in the presence of hydrogen 
peroxide in a molar ratio of 1:10. The base samples exposed to hydrogen 
peroxide or UV light alone were used as corresponding controls. Poly(dA) and 
poly(dT) (0.154 mM) in PBS, pH 7.4 were modified similarly. 
Spectroscopic Analysis 
The ultraviolet spectra of modified and unmodified controls were recorded 
in the range of 200-400 nm on a Shimadzu UV-240 spectrophotometer. 
Absorption Temperature Scan 
Thermal denaturation analysis of nucleic acids was accomplished in order 
to ascertain the degree of modification incurred on the nucleic acids by 
determining mid-point melting temperature (Tm). 
Native and ROS-DNA samples were subjected to heat denaturation under 
identical conditions on a Shimadzu UV-240 spectrophotometer coupled with a 
temperature programmer and controller assembly (Hasan and Ali, 1990). The 
samples were melted from 30°C to 95°C at a rate of l°C/min and change in 
absorbance at 260 nm was recorded. Percent denaturation was calculated using 
the following equation: 
A j - AjQ 
% denaturation = x 100 
A_.. - A, 
max '30 
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where, 
A^ = Absorbance at a temperature T°C 
^max ~ Final maximum absorbance on the completion of denaturation. 
AjQ = Initial absorbance at 30°C. 
Detection of Single Strand Breaks 
The damage to DNA mediated by hydroxy! radical was ascertained by 
alkaline sucrose density gradient centrifugation and nuclease SI sensitivity 
assay. 
(a) Alkaline Sucrose Density Gradient Ultracentrifugation 
Native and ROS-DNA (0.2 ml of 100 /xg/ml) were treated with an equal 
volume of 0.2 N NaOH and layered on top of a linear 4.6 ml alkaline sucrose 
gradient (5-20% sucrose in 800 mM NaCl, 200 mM NaOH and 10 mM EDTA) 
(AH and Sauerbier, 1978). The gradients were centrifuged at 30,000 rpm for 1 
hr at 20°C in SW 50.1 rotor of a Beckman ultracentrifuge. The tubes were 
pierced from the base and 0.5 ml fractions were collected and absorbance 
monitored at 260 nm. 
(b) Nuclease SI Sensitivity of Modified DNA Samples 
Native and ROS-DNA were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). Thirty /il of sample containing approximately 3 /xg 
DNA in acetate buffer (30 mM each of sodium acetate and zinc chloride, pH 
5.0) was treated with 20 units of nuclease SI per /xg of DNA for 30 min at 
37°C. The reaction was stopped by the addition of one-tenth volume of 200 mM 
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EDTA, pH 8.0. The digested and control samples were subjected to agarose gel 
electrophoresis. 
(i) Gel preparation 
Agarose (1%) in 30 ml of TAE (40 mM Tris acetate, pH 8.0 containing 2 
mM EDTA) was dissolved by heating. The solution was cooled to about 50°C 
and then poured into the gel tray and left at room temperature for 30 min for 
complete solidification. 
(ii) Sample preparation and loading 
Nucleic acid samples treated with nuclease SI were mixed with one-tenth 
volume of loading buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA and lOx electrophoresis buffer). The samples were loaded in the wells of 
the submerged gel (0.4 cm thick) and electrophoresed for 2 hr at 30 mA. The 
gel was stained directly by immersion in electrophoresis buffer containing 1 (igl 
ml ethidium bromide and viewed by illumination under UV light. 
Separation of Modified Bases 
The separation and quantitation of modified bases in nucleic acid samples 
was carried out according to Hasan and Ali (1990). 
(a) Acid hydrolysis of nucleic acid samples 
Reactive oxygen species modified and native DNA samples were treated 
with 60% perchloric acid by heating at 100°C for 1 hr to release the bases. The 
solution was then neutralized and the bases were separated on DEAE-Sephadex 
A-25 column. 
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(b) DEAE-Sephadex A-25 column chromatography 
The swollen ion exchanger was mixed with starting buffer (1.0 mM Tris-
HCl, pH 7.6) to form a fairly thick slurry. The suspension was poured into the 
column and gel was allowed to settle. About ten bed volumes of buffer were 
run through the column to equilibrate and stabilize the bed. Three ml of sample 
was loaded onto the column and eluted with a linear gradient of 1.0-20.0 mM 
at a flow rate of 40 ml/hr. Three ml fractions were collected and absorbance 
read at 260 nm. The control experiments were carried out with individual bases 
and hydrolyzed native DNA in order to locate the pattern of unmodified bases. 
Isolation and Purification of Monoclonal and SLE IgG 
Monoclonal antibody against 400 bp ROS-DNA was obtained as described 
earlier (Ashok, 1996). 
Immunoglobulin G was isolated from the ascitic fluid by affinity 
chromatography on Protein G Sepharose 4B chromatography and that from SLE 
serum by Protein A Sepharose CL-4B. 
The required amount of dried matrix was swollen for 15 min and washed 
with about 200 ml of 100 mM sodium phosphate buffer, pH 7.0 per gram of 
initial dried matrix, added in several aliquots and packed in the column (4 cm x 
1 cm). The packed column was equilibrated with five volumes of PBS. The 
sample was suitably diluted with PBS, slowly passed through the column and 
recycled 3-4 times for maximum binding. The column was washed with PBS and 
absorbance at 280 nm recorded till the base line value was attained. Bound IgG 
was eluted with 0.58% acetic acid in 0.85% sodium chloride in a container 
having 1 ml of 1 M Tris-HCl (pH 8.5) to neutralize the fractions. Four ml 
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fractions were collected and absorbance recorded at 280 nm. 
Isotyping 
Isotyping of monoclonal Ig was performed in a similar manner to direct 
binding ELISA except that after coating the antibody and washing the plate, the 
anti-mouse IgM and IgG sub-classes were coated and plate developed using anti 
Ig-HRP as conjugate and o-phenylenediamine/hydrogen peroxide as substrate. 
Polyacrylamide Gel Electrophoresis 
The homogeneity of the IgG was ascertained by polyacrylamide slab gel 
electrophoresis according to the method of Laemmli (1970). 
(a) Stock solutions 
(i) Acrylamide-bisacrylamide (30:0.8): 
Prepared by dissolving in distilled water 30.0 g of acrylamide and 0.8 g 
of bisacrylamide in a total volume of 100.0 ml. The solution was stored at 4°C 
in a brown bottle. 
(ii) TEMED: Used as supplied. 
(Hi) Ammonium persulphate (1.5% w/v): 
0.15 g of ammonium persulphate was dissolved in 10.0 ml water. The 
solution was made fresh just before use. 
(iv) SDS (10% w/v): 
Prepared by dissolving 10.0 g SDS in 100.0 ml distilled water. 
(v) Resolving gel buffer (3 M Tris-HCl, pH 8.8): 
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Prepared by dissolving 36.0 g Tris in 48.0 ml of 1 N HCl. The contents 
were mixed thoroughly, pH brought to 8.8 and final volume made upto 100.0 
ml with distilled water. 
(vi) Stacking gel buffer (0.5 M Tris-HCl, pH 6.8): 
Tris (6.05 g) was dissolved in 40.0 ml distilled water, titrated to pH 6.8 
with 1 N HCl and volume made upto 100.0 ml with distilled water. 
(vii) Reservoir buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3): 
3.03 g Tris, 14.4 g glycine and 1.0 g SDS were dissolved in distilled 
water and final volume made upto one litre. 
(b) Recipe for 7.5% Resolving gel 
Acrylamide-bisacrylamide 7.5 ml 
Resolving gel buffer 3.75 ml 
10% SDS 0.3 ml 
1.5% An.monium persulphate 1.5 ml 
Distilled water 16.95 ml 
TEMED 15.0 lil 
(c) Recipe for 2.5% stacking gel 
Acrylamide-bisacrylamide 2.5 ml 
Stacking gel buffer 5.0 ml 
44 
10% SDS 0.2 ml 
1.5% Ammonium persulphate 1.0 ml 
Distilled water 11.3 ml 
TEMED 15.0 /xl 
(d) Procedure 
The resolving gel mixture was prepared by mixing the components in the 
appropriate volumes as listed above and poured into the space between the glass 
plates leaving sufficient space (about 3.5 cm) at the top for the stacking gel. 
After the polymerization of separating gel, stacking gel mixture was poured and 
allowed to solidify. Protein samples containing 10% glycerol and 0.002% 
bromophenol blue were applied and electrophoresis was carried out at 60 V for 
6-8 hr. Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue R 
250 (in 25% isopropanol and 10% glacial acetic acid) and the gel was destained 
using a mixture of 10% glacial acetic acid and 30% methanol. 
Immunological Detection of Antibodies 
Sera were tested for antibodies by immunodiffusion, counter 
immunoehctrophoresis, enzyme linked immunosorbent assay, gel retardation 
assay and dot blot assay. 
(a) Immunodiffusion 
Immunodiffusion was carried out by Ouchterlony immunodiffusion system. Six 
ml of 0.4% molten agarose in PBS containing 0.1% sodium azide was poured onto glass 
petri dishes and allowed to solidify at room temperature. Wells of 5 mm diameter were 
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cut into the hardened agarose gel and an appropriate concentration of antigen and 
antibody was placed in the wells. The petridishes were allowed to stand in a moist 
chamber at room temperature for 48-72 hr. The gels were washed with 5% sodium 
citrate for 2 hr to remove non-specific precipitin lines. The result was analyzed visually. 
(b) Counter immunoelectrophoresis 
Counter immunoelectrophoresis was performed by the method of Kurata and Tan 
(1976) using 0.6% molten agarose in 25 mM barbital buffer, pH 8.4 containing 0.1% 
sodium azide and poured onto 2.5 mm thick glass slides (2.5 cm x 7.5 cm) and allowed 
to harden at room temperature. The slides were stored at 4°C and wells of 3 mm 
diameter were cut on the slides at a distance of 5 mm between the two opposite wells. 
Antigen was placed in the cathodal well and antibodies in the anodal well. 
Electrophoresis was performed for 30 min in 50 mM barbital buffer, pH 8.4 with a 
current of 3-4 mA per slide. Non-specific precipitin lines were removed by treatment 
with 5% sodium citrate solution. 
(c) Enzyme linked immunosorbent assay 
(i) Buffers and reagents 
Tris buffered saline (TBS): 
Tris buffered saline Tween-20: 
(TBS - T) 
Carbonate-Bicarbonate buffer: 
10 mM Tris 
150 mM NaCl, pH 7.4 
20 mM Tris 
144 mM NaCl 
2.68 mM KCl, pH 7.4 
containing 500 /xl Tween-20/litre 
15 mM sodium carbonate 
35 mM sodium bicarbonate 
pH 9.6 containing 2 mM 
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magnesium chloride. 
Citrate-phosphate buffer: 50 mM citric acid 
50 mM NajHPO^, pH 5.0 
Substrate: 500 /xg p-nitrophenyl phosphate per ml 
of carbonate-bicarbonate buffer or 500 ng 
o-phenylenediamine per ml of citrate-
phosphate buffer containing 1 /xl/ml of 
hydrogen peroxide. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as 
solid support (Aotsuka et al., 1979). One hundred /xl of 2.5 /xg/ml antigen (in 
TBS) was coated in test wells of microtitre plates, incubated for two hr at 37°C 
and overnight at 4°C. The plate was washed three times with TBS-T to remove 
any unreacted antigen. Unoccupied sites were blocked with 150 ix\ of 1.5% BSA 
in TBS for 4-5 hr at room temperature. The plates were washed once with TBS-
T and antibodies (100 /iil/well) to be tested were diluted in TBS and added to 
each well. After 2 hr incubation at 37°C and overnight at 4°C, the plates were 
washed four times with TBS-T and an appropriate anti-immunoglobulin alkaline 
phosphatase conjugate or anti-Ig HRP-conjugate was added to each well. After 
incubation at 37°C for 2 hr, the plates were washed four times with TBS-T and 
twice with distilled water and developed using p-nitrophenyl phosphate or o-
phenylenediamine/hydrogen peroxide as substrate. The plates were incubated 
for 1-2 hr and reaction stopped in the case of o-phenylenediamine/hydrogen 
peroxide system with 100 /xl of 5 N HjSO^ and read at 490 nm. In the case of 
p-nitrophenyl phosphate, the absorbance was recorded at 410 nm on an 
automatic microplate reader. Each sample was run in duplicate. The control 
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wells were treated similarly but were devoid of antigen. Results were expressed 
as a mean of A,^ ,^ - Ac„„,,„,. 
Competition ELISA 
The antibodies specificity was determined by competition ELISA 
employing modified polymers, bases and various synthetic polynucleotides as 
inhibitors as described earlier (Hasan et al., 1991). A constant amount of the 
antibody was incubated with increasing amounts (0-20 ng) of the inhibitors for 
2 hr at 37°C and overnight at 4°C. The mixture was added to the ELISA plates 
instead of the antibodies and the direct binding ELISA was performed. 
Percent inhibition was calculated using the formula 
AQ - A^ 
% inhibition = x 100 
Ao 
(d) Gel retardation assay 
For the visual detection of antigen-antibody binding and formation of 
immune complexes, gel retardation assay was performed (Alam and Ali, 1992). 
A constant amount of antigen (ROS-DNA or native DNA) was incubated with 
varying amounts of IgG in PBS, pH 7.4 for 2 hr at 37°C and overnight at 4°C. 
One-tenth volume of dye solution was added to the mixture and electrophoresed 
on 1% agarose for 2 hr at 30 mA in TAE buffer, pH 7.9. The gels were stained 
with ethidium bromide ( XjxglmX), visualized under UV light and photographed. 
Appropriate controls were run simultaneously. 
For the visual detection of ROS-thymine and ROS-poly(dT) binding to 
SLE autoantibodies, an indirect band shift assay was performed. Immune 
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complex was prepared by incubating ROS- thymine (10 pig) and ROS-poly(dT) 
(1.5 /ig) with increasing amounts of SLE IgG (10, 15 and 20 ^g) at 37°C for 2 
hr followed by overnight incubation at 4°C. After incubation, 0.2 ^g of native 
DNA (size ~ 200 bp) was added. The mixture was incubated for 90 min at 37°C 
and electrophoresed as described above. 
(e) Dot blot assay 
Dot blot assay was essentially performed as described by Juarez et al. 
(1994). Five ng each of the antigens, ROS-modified poly(dT), ROS-DNA and 
nDNA were spotted separately onto nitrocellulose membrane and air dried. 
Unoccupied sites on the membrane were blocked with 1.5% BSA. Subsequently, 
tht membrane was incubated with 1:50 diluted antibodies for 2 hr at 37°C and 
overnight at 4°C. Unbound antibodies were washed with TBS-T, pH 7.4 and 
incubated with appropriate anti-lgG-HRP conjugate. The reaction was developed 
with 4-chloro-l-naphthol/hydrogen peroxide as substrate (prepared by adding 6 
mg 4-chloro-l-naphthol in 2 ml methanol and 10 ml TBS and 20 /xl hydrogen 
peroxide). A control assay was simultaneously carried out without spotting 
antigen on the membrane and developed in a similar manner as the test. 
Chemical Modification of Monoclonal IgG 
Acetylation of IgG to modify its lysine residues was performed according 
to the method of Riordan and Vallee (1972) using acetic anhydride as the 
acetylating agent. A solution of IgG of known amount (500 y.g) in 200 mM 
sodium phosphate buffer, pH 7.5 was taken and to this was added the required 
amount of acetic anhydride with continuous stirring. Reaction was performed at 
4°C and pH of the reaction mixture was maintained between 7.4 to 7.6 by the 
addition of 1 N NaOH. The reaction was allowed to proceed for 30 min. 
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Similarly, the molar excess of acetic anhydride over protein was varied from 
50 to 800 to obtain different degrees of modification. The modified protein was 
dialyzed against sodium phosphate buffer, pH 7.5. 
Quantification of Modification 
The extent of lysyl residue modification of anti-ROS DNA IgG was 
determined by using trinitrobenzene sulphonic acid (TNBS) as described by 
Habeeb (1966). 
Varying concentrations of the protein solution (modified and native IgG) 
were diluted with distilled water to a final volume of 1.0 ml. To this was added 
1.0 ml of 4% NaHC03, pH 8.5 and 1.0 ml of 0.1% TNBS solution. The reaction 
mixture was incubated for 2 hr at 37°C. Subsequently, 1.0 ml of 10% SDS was 
added to solubilize the protein and to prevent its precipitation on addition of 
0.5 ml of 1 N HCl. The color intensity was recorded after 10 min at 335 nm 
against a blank treated in the same manner except that it contained 1.0 ml of 
water instead of the protein solution. Percent modification was calculated using 
the following equation: 
Percent modification = 100 [l-(m/mjj)] 
where, m and m^ , represent the slopes of the straight lines of modified and 
unmodified preparations respectively. 
Isolation of DNA from Human Lymphocytes 
(a) Isolation of lymphocytes 
Blood from SLE patients and normal healthy individuals was collected in 
tubes containing heparin and gently shaken for proper mixing of anticoagulant. 
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It was diluted two fold with sterile PBS. In a separate tube was added 
Ficollpaque density gradient (1/2 volume) and diluted blood was added from the 
side without disturbing the gradient. The gradient was centrifuged at 1800 rpm 
for 30 min at 25°C. After centrifugation, the lymphocyte layer at the interface 
was removed and diluted two fold with PBS. This was centrifuged again at 2500 
rpm for 10 min and pellet was collected which was washed twice with PBS and 
spinned at 1000 rpm for 10 min. The pellet was then resuspended in PBS and 
stored at -80°C for further use. 
(b) Isolation of human DNA 
Human DNA was isolated from lymphocytes essentially as described by 
Baas et al. (1984). Lymphocytes were lysed by lymphocyte lysis buffer (10 mM 
Tris, 2 mM EDTA, 400 mM NaCl, containing 1% SDS and 1 mg/ml proteinase 
K) and incubated at 50°C for 1 hr and 37°C overnight with constant shaking. 
To this was added an equal volume of chloroform-isoamyl alcohol (24:1), 
extracted for 15 min and allowed to stand for 15-30 min. The aqueous layer was 
carefully removed and extraction step repeated two to three times. To the 
aqueous layer was added one-tenth volume of 3 N sodium acetate buffer, pH 
5.2 and two volumes of cold absolute ethanol to precipitate DNA. The DNA was 
collected by centrifugation, washed once with 70% ethanol and allowed to dry. 
It was then dissolved in PBS, pH 7.4. The absorbance of DNA solution was 
measured at 260 nm and 280 nm to ascertain its purity and to determine its 
concentration. 
Immunization Schedule 
ROS-DNA (50 /ig/rat) complexed with equal amount of methylated BSA 
(w/w) and emulsified with equal volume of Freund's complete adjuvant was 
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injected subcutaneously in female (Sprague Dawley) rats. Three booster doses 
(25 ^g/rat) were given intra-peritoneally at weekly intervals with incomplete 
adjuvant. Control group was one which did not receive any antigen. Animals 
were bled through orbital sinus and blood collected. Serum was separated and 
decomplemented by heating at 56°C for 30 min and stored at -80°C with 0.1% 
sodium azide as preservative. Preimmune sera were collected prior to 
immunization. Immune response was determined by direct binding ELISA 
employing ROS-DNA as antigen. 
Rats were sacrificed and their kidney and liver removed and stored at 
70°C. 
Immunofluorescence 
Kidney sections (approx. 5 microns thick) of rat were fixed On slides with 
acetone and incubated with anti-rat IgG fluorescein isothiocyanate conjugate 
(1:100 diluted) for 30 min. Subsequently slides were washed three times with 
PBS and mounted with 50% glycerol. The slides were then viewed under a 
fluorescent microscope. 
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Antigen Formation and its Characterization 
A solution of purified calf thymus DNA (0.15 mM bp) in PBS, pH 7.4 
was irradiated at room temperature with UV light of wavelength 254 nm in the 
presence of hydrogen peroxide. The irradiated samples were dialysed 
extensively against PBS to remove excess of hydrogen peroxide. The UV 
absorption spectra was recorded using Shimadzu UV-240 spectrophotometer. 
Figure 5 shows the absorption spectra of modified and control DNA samples. 
As compared to native DNA, the ROS-modified DNA sample showed a marked 
decrease in absorbance at 260 nm. However, exposure of DNA to hydrogen 
peroxide without UV irradiation caused only a slight decrease in the absorbance. 
No change in UV absorption profile of DNA was noticed on irradiation alone. 
The bases (adenine, thymine) and their respective homopolymers 
[poly(dA), poly(dT)] were irradiated in a similar manner and the UV absorption 
spectra of the modified bases and polymers and their corresponding controls 
were recorded. Irradiation of bases alone or their incubation with hydrogen 
peroxide without irradiation showed a minor decrease in absorption at 260 nm 
which could be either due to the formation of respective dimers or other 
oxidation products. However, irradiation in the presence of hydrogen peroxide 
resulted in complete disappearance of characteristic absorption spectra. A 
generalized absorption getting stronger towards shorter wavelength was 
observed. Almost similar changes were noted in case of adenine and thymine 
(Figs. 6 and 7). Interaction of poly(dA) with hydroxyl radical showed 
broadening of absorption maxima, drastic reduction in absorption at 260 nm and 
a slight shift of 10 nm in the apparent minima from 230 nm to 240 nm (red 
shift) (Fig. 8). In case of poly(dT) almost complete disappearance of absorption 
maxima in comparison to control sample was observed. The modified poly(dT) 
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2.000 
200.0 300.0 
WAVELENGTH ( n m ) 
400.0 
Fig. 6. UV absorption spectra of native and ROS-adenine. 
Adenine (—), UV-irradiated adenine (—), adenine-H^O^ complex 
(—•—), ROS-adenine (—••—). 
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WAVELENGTH ( n m ) 
400.0 
Fig. 7. UV absorption spectra of native and ROS-thymine. 
Thymine (—), UV-irradiated thymine ( — ) , thymine-H^O^ complex 
( _ , _ ) , ROS-thymine (—..—). 
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Fig. 8. UV absorption spectra of native 
Poly(dA) ( - ) , ROS-poly(dA) (—)• 
and ROS-poly(dA). 
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showed almost no absorption from 230 to 300 nm (Fig. 9). 
Thermal Melting of DNA 
Thermally induced transitions were measured spectrophotometrically at 
260 nm by heating nucleic acid samples at a rate of 1°C per min. Melting curves 
were recorded at temperatures from 30°C to 95°C. Increase in UV absorption 
at 260 nm was taken as a measure of denaturation. Figure 10 shows the thermal 
denaturation profile of native DNA and ROS-modified DNA. The melting 
temperature of native DNA at which fifty percent of the double helical structure 
is lost was found to be 87.5°C, while in the case of ROS-DNA it was found to 
be 74°C. The results exhibit a net decrease of 13.5°C in the Tm value for the 
modified DNA when compared to its unmodified native conformer. These 
findings indicate, therefore, that the decrease in Tm to the extent of 13.5°C is 
primarily due to a structural alteration of DNA which occurs upon generation 
of single strand breaks. The percent hyperchromicity and Tm values of native 
and modified DNA are shown in Table 3. 
Single strand breaks 
(a) Sedimentation behaviour 
ROS- and native DNA samples were subjected to alkaline sucrose gradient 
ultracentrifugation. Samples were denatured by the addition of 0.2 N NaOH, 
transferred to the top of a 5-20% linear alkaline sucrose gradient and sedimented 
at 30,000 rpm for 1 hr. Absorbance was recorded at 260 nm and data plotted as 
absorbance at 260 nm against fraction number. Figure 11 shows the 
sedimentation profile for native and modified DNA. Changes in molecular 
weight of DNA due to single strand breaks by hydroxyl radical can be observed 
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Fig. 9. UV absorption spectra of native and ROS-poly(dT). 
Poly(dT) ( - ) , ROS-poly(dT) (—) . 
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Temperature (**C) 
Fig. 10. Thermal denaturation profile of native (O) and native ROS-DNA 
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TABLE 3 
Ultraviolet and Thermal Denaturation Characteristics of 
Native and ROS-modified Nucleic Acids 
Parameter Native DNA ROS-DNA 
1. Absorbance ratio at 260/280 
2. Percent hyperchromicity at 95°C 
3. Melting temperature (Tm), °C 
4. Onset of duplex melting 
1.82 
16.4 
87.5 
82.0 
1.9 
14.5 
74.0 
55.0 
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as a change in the sedimentation rate. Native DNA banded as a sharp 
symmetrical peak at fraction 3 while modified DNA gave a broader peak at 
fraction 8 indicating the generation of single strand breaks which causes changes 
in the molecular weight and hence the diffused pattern. 
(b) Nuclease SI digestion of DNA samples 
Calf thymus DNA treated with hydrogen peroxide and exposed to 254 nm 
light was digested with nuclease SI (20 units//ig DNA) for 30 min. The residual 
DNA was subjected to agarose gel electrophoresis. Control experiments were 
carried out with native DNA, nuclease SI treated native DNA and ROS-DNA. 
Figure 12 shows the nuclease 81 susceptibility of modified and native DNA 
samples. In case of modified DNA there was a loss in intensity of DNA band, 
while native DNA was essentially unaffected by nuclease SI treatment. Thus it 
could be inferred that hydroxyl radical treatment to DNA caused sufficient 
structural alterations in DNA to be a substrate for nuclease SI. 
Modification of Purine and Pyrimidine Bases in Native DNA by ROS 
In order to separate the modified bases, ROS-DNA solution was subjected 
to acid hydrolysis. The neutralized hydrolyzate was applied to a DEAE-
Sephadex A-25 column and eluted by a linear gradient of 1-20 mM Tris-HCl 
buffer, pH 7.6. Control experiments were carried out by passing individual 
bases and hydrolyzed native DNA (Figs. 13 and 14). The elution profile of 
native DNA was similar to that obtained with individual bases. Peaks 1, 2, 3 
and 4 represent cytosine, thymine, adenine and guanine respectively. 
Exposure of DNA to hydrogen peroxide in the presence of UV light 
resulted in the formation of additional base products (Fig. 15), separated by 
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Fig. 12. Nuclease SI digestibility of native and ROS-DNA. Lane 1 contained 
nDNA (3 fig), lane 2 contained nDNA treated with nuclease SI, 
lane 3 contained ROS-DNA (3 ng), and lane 4 contained ROS-DNA 
treated with nuclease SI for 30 min. 
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Fraction Number 
Fig. 13. Elution profile of standard individual nitrogenous bases on DEAE-
Sephadex A-25 column. Cytosine (a), thymine (b), adenine (c) and 
guanine (d). 
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Fig. 14. Fractionation of acid hydrolysed native DNA an DEAE- Sephadex 
A-25 column. Peaks 1, 2, 3 and 4 represent cytosine, thymine, 
adenine and guanine. 
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Fig. 15. Elution profile of unmodified and modified bases from acid 
hydrolyzed native ROS-DNA on DEAE-Sephadex A-25 column. 
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represent modified and unmodified guanine. 
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elution on DEAE-Sephadex A-25 column after acid hydrolysis. The products 
were identified spectrophotometrically and by comparison with the 
chromatographic patterns of the standard bases. The first peak collected from 
the column represents modified cytosine followed by unmodified cytosine. The 
third and fourth peak correspond to modified and unmodified thymine 
respectively, while the fifth and sixth peaks represent modified and unmodified 
adenine. The last two peaks show modified and unmodified guanine respectively. 
The extent of modification was determined by measuring the peak areas of the 
modified and the corresponding unmodified controls. It was found that thymine 
was modified to the greatest extent (46.8%), followed by guanine (30.6%), 
cytosine (19.8%) and adenine (16.7%) (Table 4). 
Isotyping of the Monoclonal Antibody 
Monoclonal antibodies generated against 400 bp ROS-DNA were used for 
this study. Isotyping of the monoclonal antibody was performed to determine 
the immunoglobulin sub-class. The data showed the clones to be of IgGl sub-
class (Table 5). 
Purification of Monoclonal Antibodies 
The purification of monoclonal IgG from ascitic fluid of the three clones 
PjCjjDg, PjC^Ej and PjHjF,, was done by affinity chromatography on Protein 
G-Sepharose 4B column. Figure 16 shows the elution profile of IgG from 
P3CjjDg. Purified IgG was found to elute in a single symmetrical peak. The 
purity of the isolated IgG was ascertained by SDS-PAGE under non-reducing 
conditions which resulted in a single band (Fig. 16 inset). 
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TABLE 4 
Modification of Bases in DNA Exposed to Hydroxyl Radical 
Base Percent modification 
Cytosine 19.8 
Thymine 46.8 
Adenine 16.7 
Guanine 30.6 
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TABLE 5 
Isotyping of Monoclonal Antibodies 
Clone Isotype 
P3C„D, IgGl 
P3H,F„ IgGl 
P,C,E, IgGl 
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Fig. 16. Elution profile of anti-ROS-DNA monoclonal IgG from 
clone PjCjjDg on Protein G-Sepharose 4B affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% acrylamide gel. 
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Characterization of Monoclonal Antibody 
The antibodies induced against 400 bp ROS-DNA were non-precipitating 
as detected by immunodiffusion and counter immunoelectrophoresis. Direct 
binding ELISA was performed to determine the binding of monoclonal IgG to 
the antigen. Out of the three clones, PjCijD^ and PjC^Ej showed appreciable 
antibody binding to the immunogen (Figs. 17 and 18). Competition ELISA 
experiments showed positive results with only PjCjjD^ and not with PjC^Ej. 
Hence the latter clone was discontinued for further studies and all other 
experiments were carried out with PjCjjD^. 
Competition ELISA experiments were performed to characterize the 
antigenic specificity of the monoclonal antibody. When ROS-DNA was used as 
an inhibitor, a maximum inhibition of 84% in antibody binding to the antigen 
was seen (Fig. 19) and the concentration of ROS-DNA required to inhibit 50% 
antibody activity was 3.0 /xg/ml. Four hundred bp ROS-DNA and 200 bp ROS-
DNA showed maximum inhibitions of 76.5% and 59.7% respectively (Fig. 19) 
and the concentration required for 50% inhibition was found to be 4.4 and 10.0 
/lig/ml respectively. Thus it can be seen that a decrease in the size of DNA 
fragment caused a relative decrease in maximum percent inhibition. When native 
DNA was taken as an inhibitor, a maximum of 65.1% inhibition was observed 
and the concentration required for 50% inhibition was 8.0 /xg/ml. 
The antigen binding specificity of the monoclonal antibody was also tested 
by using a variety of native and ROS-modified nitrogenous bases and 
polydeoxyribonucleotides. ROS-thymine proved to be an effective inhibitor of 
monoclonal antibody binding to ROS-DNA showing a maximum of 66.5% 
inhibition (Fig. 10) and the concentration required for 50% inhibition was 9.0 
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Fig. 17. Binding of monoclonal antibody (clone PjCjjDg) (O) and preimmune 
IgG (•) to 400 bp ROS-DNA. 
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Fig. 18. Binding of monoclonal antibody (clone PiC^E )^ (O) and preimmune 
IgG (•) to 400 bp ROS-DNA. 
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Fig. 19. Inhibition of anti-ROS-DNA monoclonal antibody (PjC^jD^) binding 
to 400 bp ROS-DNA. The competitors were ROS-DNA (O), 400 bp 
ROS-DNA (•) , 200 bp ROS-DNA (A) and nDNA (O). Microtitre 
plates were coated with 400 bp ROS-DNA (2.5 pig/ml). 
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Fig. 20. Inhibition of anti-ROS-DNA monoclonal antibody (PjCjjD^) binding 
to 400 bp ROS-DNA. The competitors were RNA (6) , ROS-thymine 
( • ) , ROS-poly(dT) (A) and ROS-thymidine (A) . 
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/ug/ml. On the other hand, unmodified thymine showed a low level of inhibition 
i.e. 31.9% (Fig. 21). Similarly ROS-thymidine and ROS-poly(dT) showed 
maximum inhibitions of 57.2% and 68.2% respectively (Fig. 20) and the 
concentration required to inhibit 50% of the antibody activity was found to be 
9.0 /ig/ml in the case of ROS-thymidine, while for ROS-poly(dT) it was seen to 
be very low i.e. 3.6 /ig/ml (Fig. 20). Their unmodified forms showed low levels 
of inhibitions i.e. 27.3% for thymidine and 34.8% for poly(dT) (Fig. 21). 
While ROS-guanine showed a maximum of 46.8% inhibition, its unmodified 
form was inhibitory only to the extent of 27.3% (Fig. 22). Other bases, cytosine 
and adenine as well as their modified forms exhibited an insignificant level of 
inhibition as did poly(dA) and ROS-poly(dA). The ribonucleotide homopolymer 
poly(G) and its modified form showed a maximum of 27.0 and 47.2% inhibition, 
while poly(dG) was inhibitory to the extent of 32.9 (Fig. 23). 
The cross-reactivity of the monoclonal antibody was further checked by 
using various synthetic double stranded polymers. Poly(dG).poly(dC) showed a 
maximum inhibition of 48.7%, while poly(dA-dC).poly(dG-dT) was inhibitory 
to the extent of 52.3% (Fig. 24). The concentration required to inhibit 50% of 
the antibody activity was found to be 12.0 fig/m\. Poly(dA-dG).poly(dC-dT) and 
poly(dA-dU).poly(dA-dU) wxire also relatively effective inhibitors of antibody 
binding to ROS-DNA showing a maximum of 49.8% and 46.0% inhibition 
respectively (Fig. 24). Other polymers i.e. poly(dI-dC).poly(dI-dC), poly(dG-
dC).poly(dG-dC) and poly(rG).poly(dC) exhibited maximum inhibitions of 
30.0%, 64.2% and 53.3% respectively at 5 /xg/ml. A further increase in 
inhibitor concentrations gave slightly haphazard results and thus were not 
considered. Inhibition study using two plasmids-pBR322 and pBS gave 
interesting results (Fig. 25). While pBR322 showed an inhibition of 62%, pBS 
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Fig. 21 . Inhibition of anti-ROS-DNA monoclonal antibody (PjCjjDg) binding 
to 400 bp ROS-DNA. The competitors were thymine ( A ) , thymidine 
( • ) and poly (dT) (O). 
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Fig. 22. Inhibition of anti-ROS-DNA monoclonal antibody (PjCjjD^) binding 
to 400 bp ROS-DNA. The competitors were cytosine (O), ROS-
cytosine ( • ) , guanine (A) and ROS-guanine (A). 
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Fig. 23. Inhibition of anti-ROS-DNA monoclonal antibody (P3CjjDg) binding 
to 400 bp ROS-DNA. The competitors were poly(G) ( • ) , ROS-
poly(G) (9) and poly(dG) (A). 
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Fig. 24. Inhibition of anti-ROS-DNA monoclonal antibody (PjCijDg) binding to 
400 bp ROS-DNA. The competitors were poly(dG).poly(dC) 
(0),poly(dA-dC).poly(dG-dT) (•) , poly(dA-dG).poly(dC-dT) (A) and 
poly(dA-dU).poly(dA.dU) (A). 
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Fig. 25. Inhibition of anti-ROS-DNA monoclonal antibody (P3Cj,Dg) binding 
to 400 bp ROS-DNA. The competitors were plasmid DNA pBR322 
(O) and pBS (•) . 
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was non-inhibitory. Table 6 summarizes the results of the inhibition studies of 
anti-ROS-DNA monoclonal antibody with various inhibitors. 
Band Shift Assay 
The visual detection of antigen-antibody interaction was performed by a 
band shift (gel retardation) assay. Constant amounts of the antigen were 
incubated with varying amounts of monoclonal IgG for 2 hr at 37°C and 
overnight at 4°C. These immune complexes were then electrophoresed on 1.0% 
agarose for 2 hr at 30 mA. Figure 26 shows the binding of monoclonal IgG to 
400 bp ROS-DNA. As seen from the photograph, an increase in the IgG 
concentration resulted in an increase in the formation of immune complexes. 
This causes a relative increase in the molecular weight as deduced from the non-
entry of immune complex in the separating system. These results of retarded 
mobility strengthen the direct binding and inhibition ELISA results. 
Modification of Lysine Residues 
In order to investigate the contribution of lysine residues to the 
immunochemical reactivity of anti-ROS-DNA monoclonal antibody, the free 
amino groups of lysine residues were modified with acetic anhydride. Different 
degrees of modification were achieved by changing molar excess of acetic 
anhydride over protein (from 50-800 molar excess). The extent of modification 
was determined by trinitrobenzene sulphonic acid (Habeeb, 1966). Figure 27 
shows the relationship between molar excess of acetic anhydride and the percent 
modification of lysine residues. The extent of modification was calculated using 
the following formula. 
Percei\t modification = 100 [l-Cm/m^)] 
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TABLE 6 
Inhibition of Anti-ROS-DNA Monoclonal Antibody Binding to 
ROS-DNA by Variety of Nucleic Acid Polymers 
Maximum percent 
Inhibitors 
400bp ROS-DNA 
Native-ROS-DNA 
200bp ROS-DNA 
Native-DNA 
Thymine 
ROS-thymine 
Poly(dT) 
ROS-poly(dT) 
Thymidine 
ROS-thymidine 
Guanine 
ROS-guanine 
Cytosine 
ROS-cytosine 
Adenine 
ROS-adenine 
Poly(dA) 
ROS-poly(dA) 
RNA 
Poly(G) 
ROS-poly(G) 
Poly(dG) 
Poly(dG).poly(dC) 
inhibition 
at 2C 
Poly(dA-dC).poly(dG-dT) 
Poly(dI-dC).poly(dI-dC) 
Poly(dA-dG).poly(dC-dT) 
Poly(dA-dU).poly(dA-dU) 
Poly(dG-dC).poly(dG-dC) 
Poly(rG).poly(dC) 
I /ig/ml 
76.5 
84.0 
59.7 
65.1 
31.9 
66.5 
34.8 
68.2 
27.3 
57.2 
27.3 
46.8 
19.8 
24.2 
# 
# 
# 
29.2 
17.2 
27.0 
47.2 
32.9 
48.7 
52.3 
30.0* 
49.8 
46.0 
64.2* 
53.3* 
Concentration for 
50% inhibition 
(Atg/ml) 
4.4 
3.0 
10.0 
11.0 
-
9.0 
-
3.6 
-
9.0 
-
-
-
-
-
-
-
-
-
-
-
-
-
12.0 
-
-
-
-
-
Percent relative 
affinity 
100.0 
146.6 
44.0 
40.0 
-
48.8 
-
122.2 
-
48.8 
-
-
-
-
-
-
-
-
-
-
-
-
-
36.6 
-
-
-
-
-
* at 5 fig/ml. 
# insignificant inhibition was observed. 
The microtitre plates were coated with 400 bp ROS-DNA (2.5 /xg/ml). 
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Fig. 26. Band shift assay of anti-ROS-DNA monoclonal IgG binding tp 400 
bp ROS-DNA. Lane 1 contained 3 /xg ROS-DNA, while lanes 2-5 
contained 3 /ug ROS-DNA incubated with 25, 50, 75 and 100 ng 
IgG for 2 hr at 37°C and overnight at 4°C. Immune complexes were 
electrophoresed on 1% agarose for 2 hr at 30 mA. 
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Molar Excess of Acetic Anhydride 
Fig. 27. Determination of extent of lysine modification at different 
concentrations of acetic anhydride. 
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where, m and m^ represent the slopes of the straight lines for modified and 
unmodified samples respectively. 
It is evident from Figure 27 that with an increase in molar excess of 
acetic anhydride, there is a progressive increase in modification of lysine 
residues and the maximum extent of modification achieved was 79.3% at 800 
molar excess of acetic anhydride (Table 7). 
Effect of Lysine Modification on the Binding of Anti-ROS-DNA 
Antibody 
The ability of acetylated IgG to react with ROS-DNA was investigated by 
direct binding ELISA. Figure 28 shows that the activity of the modified IgG 
decreased with an increase in modification of lysine residues. With the 
acetylation of 59.5% and 67.6% of lysine residues, considerable inhibition in 
antibody binding was observed as reflected by a decrease in absorbance at 410 
nm. Acetylation of 79.3% of lysine residues at 800 molar excess resulted in 
approximately 72.8% loss of antibody binding. Table 8 represents the 
summarized data on the percent decrease in antibody binding as a consequence 
of lysine modification. 
Characterization of Human SLE Anti-DNA Autoantibodies 
The SLE anti-DNA autoantibodies were also found to be non-precipitating 
as detected by immunodiffusion and counter Immunoelectrophoresis. The binding 
pattern of human serum antibodies to native DNA from ten patients with SLE 
was determined by direct binding ELISA. The results showed a high titre of 
anti-DNA antibodies in eight out of ten cases (Figs. 29 and 30; Table 9). In 
contrast, no binding was observed with the sera of normal subjects (Table 10). 
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TABLE 7 
Chemical Modification of Lysine Residues of 
Anti-ROS-DNA Monoclonal IgG 
Acetic anhydride concentration Percent 
(molar excess over IgG) modification 
50 27.9 
100 36.4 
200 45.7 
400 59.5 
600 67.6 
800 79.3 
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Determination of effect of lysine modification on the reactivity of 
anti-ROS-DNA monoclonal antibody. The curves represent native 
IgG (1), 27.9% acetylated (2), 36.43% acetylated (3), 45.7% 
acetylated (4), 59.5% acetylated (5), 67.6% acetylated (6) and 
79.3% acetylated (7). 
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TABLE 8 
Effect of Lysyl Residues Modification on Anti-ROS-DNA 
Monoclonal Antibody Binding to ROS-DNA 
Acetic anhydride 
concentration 
(molar excess over IgG) 
Percent acetylated 
lysine residues 
Percent decrease 
in antibody 
binding 
50 27.9 12.6 
100 36.4 32.0 
200 45.7 48.5 
400 59.5 57.3 
600 67.6 64.1 
800 79.3 72.8 
The assay was performed by direct binding ELISA and microtitre plates were 
coated with ROS-DNA (2.5 lig/ml). 
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Fig. 29. Direct binding ELISA of native DNA with SLE serum 1 (O), 2 (O), 
3 (A) and 4 (A). Normal human serum ( • ) . 
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Fig. 30. Direct binding ELISA of native DNA with SLE serum 5 (3) , 6 ( • ) , 
7 (A) and 8 (4 ) - Normal human serum (O). 
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TABLE 9 
Titre of Anti-DNA Autoantibodies in Patients with Systemic 
Lupus Erythematosus 
SLE patients Titre 
1 1:3200 
2 1:1600 
3 1:6400 
4 1:1600 
5 1:1600 
6 1:3200 
7 1:6400 
8 1:1600 
9 1:400 
10 1:400 
The microtitre plates were coated with nDNA (2.5 ^g/ml). 
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TABLE 10 
Binding Capacity of Native DNA to Sera from Normal 
Subjects and Patients with Systemic Lupus Erythematosus 
Sera obtained from Number of sera tested Number of sera positive 
Normal subjects 7 0 
SLE 10 8 
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The specificity of SLE autoantibodies was determined by competition 
experiments in which binding of various SLE sera to native and modified nucleic 
acids was assayed. Eight high titre SLE sera were tested with both native and 
modified polymers as inhibitors. Native DNA showed inhibitions of more than 
50% in all the sera with the maximum inhibition reaching upto 76% with one of 
sera tested (Figs. 31 and 32; Table 11). ROS-DNA on the other hand showed 
greater inhibitions than nDNA with six SLE sera (Figs. 33 and 34; Table 12). 
Only in two cases a higher binding with nDNA was observed. Thus indicating 
that ROS-modified DNA is the preferred antigen to native DNA for SLE 
autoantibodies. 
The specificity of anti-DNA autoantibodies was further investigated using 
other inhibitors such as adenine, poly(dA), thymine, poIy(dT) and their ROS-
modified forms. It was found that adenine, poly(dA) as well as their ROS-
modified forms were not inhibitory which is similar to the antigenic specificity 
of anti-ROS-DNA monoclonal antibody. While it was seen that although thymine 
and poly(dT) were not effective inhibitors, their ROS-modified forms showed a 
relatively high percent inhibition with the monoclonal antibody and these when 
tapped for their binding with serum anti-DNA autoantibodies from SLE patients 
also exhibited varying degrees of inhibition. This could help to determine 
whether thymine modified with ROS is the major altered base involved in the 
production of anti-DNA autoantibodies. When ROS-thymine was used as an 
inhibitor of nDNA binding to SLE autoantibodies it was found that all the eight 
SLE sera showed inhibitions greater than 50% and the maximum inhibition 
achieved with one of the sera was 84% (Figs. 35 and 36; Table 13). On the 
other hand with ROS-poly(dT) a 50% inhibition could be achieved with only five 
out of the eight sera (Figs. 37 and 38; Table 14). 
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Fig. 31. Inhibition of anti-DN\ antibody binding by nDNA with SLE serum 
1 (3), 2 (O), 3 (•) and 4 (A). The microtitre plates were coated 
with native DNA (2.5 fig/ml). 
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Fig. 32. Inhibition of anti-DNA antibody binding by nDNA with SLE serum 
5 (O), 6 (O), 7 ( • ) and 8 (A) . Microtitre plates were coated with 
native DNA (2.5 /ig/n^O-
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TABLE 11 
Inhibition of SLE Anti-DNA-Autoantibody Binding 
by Native DNA 
Maximum Concentration required 
SLE serum percent inhibition for 50% inhibition 
at 20 Mg/ml (Atg/ml) 
1 55 18.0 
2 69 2.8 
3 76 2.4 
4 70 1.0 
5 60 19.0 
6 59 15.0 
7 65 6.0 
8 67 17.5 
The microtitre plates were coated with nDNA (2.5 ^g/ml). 
98 
z 
o 
ffi 
X 
z 
z 
o 
a 
Ui 
Q. 
.01 0.1 1.0 10.0 
INHIBITOR CONCENTRATION ( ug /ml ) 
Fig. 33. Inhibition of anti-DNA antibody binding by ROS-DNA with SLE 
serum 1 (O), 2 ( • ) , 3 (3) and 4 (A). Microtitre plates were coated 
with native DNA (2.5 ixg/ml). 
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Fig. 34. Inhibition of anti-DNA antibody binding by ROS-DNA with SLE 
serum 5 (O), 6 ( • ) , 7 (3) and 8 (A). Microtitre plates were coated 
with native DNA (2.5 /xg/ml). 
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TABLE 12 
Competitive Inhibition of Naturally Occurring SLE 
Autoantibodies by ROS-DNA 
SLE serum 
1 
2 
3 
4 
5 
6 
Maximum 
percent inhibition 
at 20 Mg/mi 
60 
71 
56 
60 
78 
74 
Concentration 
required for 50% 
inhibition (/tg/ml) 
14.5 
1.0 
7.2 
12.0 
13.0 
4.9 
76 3.0 
73 0.85 
The microtitre plates were coated with nDNA (2,5 /xg/ml). 
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Fig. 35. Inhibition of anti-DNA antibody binding by ROS-thymine with SLE 
serum 1 (G), 2 (O), 3 (•) and 4 (A). Microtitre plates were coated 
with native DNA (2.5 /xg/ml). 
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Fig. 36. Inhibition of anti-DNA antibody binding by ROS-thymine with SLE 
serum 5 (O), 6 ( • ) , 7 O ) and 8 (A). Microtitre plates were coated 
with native DNA (2.5 /ig/ml). 
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TABLE 13 
Inhibition of Anti-DNA Autoantibody Binding by ROS-thymine 
SLE serum 
1 
2 
3 
4 
5 
6 
7 
8 
Maximum 
percent inhibition 
at 20 Mg/ml 
50 
70 
66 
84 
55 
64 
72 
50 
Concentration 
required for 50% 
inhibition (/ig/ml) 
2.0 
11.0 
10.5 
9.0 
12.0 
15.0 
5.8 
20.0 
The microtitre plates were coated with nDNA (2.5 /ig/ml). 
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Fig. 37. Inhibition of anti-DNA antibody binding by ROS-poly(dT) with SLE 
serum 1 (Q), 2 (O), 3 ( 4 ) and 4 (• ) . Microtitre plates were coated 
with native DNA (2.5 ^g/ml). 
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Fig. 38. Inhibition of anti-DNA antibody binding by ROS-poly(dT) with SLE 
serum 5 (O), 6 ( • ) , 7 (O) and 8 (A). Microtitre plates were coated 
with native DNA (2.5 ^g/ml). 
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TABLE 14 
Competitive Inhibition of SLE Autoantibodies 
by ROS-poly(dT) 
SLE serum 
1 
2 
3 
4 
5 
6 
7 
8 
Maximum 
percent inhibition 
at 20 ftg/ml 
48 
57 
55 
48 
51 
25 
66 
64 
Concentration 
required for 50% 
inliibition (fig/ml) 
-
4.5 
2.4 
-
1.8 
-
8.5 
7.2 
The microtitre plates were coated with nDNA (2.5 ^g/ml). 
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Purification of SLE IgG 
SLE IgG was purified by affinity chromatography on Protein A-Sepharose 
CL-4B. Protein A has been known to bind IgG from most of the mammalian 
species. Figure 39 shows the elution profile of the IgG. The purified IgG was 
found to elute in a single symmetrical peak. It's purity was checked by SDS-
polyacrylamide gel electrophoresis under non-reducing conditions which resulted 
in a single band (Fig. 39 inset). 
Band Shift Assay 
Band shift assay was employed to further confirm and visualize the 
interaction of native and ROS-DNA with SLE autoantibodies. A constant amount 
of the antigen was incubated with varying amounts of the SLE IgG for 2 hr at 
37°C and overnight at 4°C. These immune complexes were then electrophoresed 
on 1.0% agarose for 2 hr at 30 mA. Figures 40 and 41 show the binding of 
anti-DNA autoantibodies to unmodified DNA of 200 bp and ROS-DNA 
respectively. As it could be seen from the photographs, an increase in the IgG 
concentration caused an increase in the immune complex formation which 
resulted in a relative increase in the molecular weight and hence a retarded 
mobility was observed. 
The visual detection of ROS-thymine and ROS-poly(dT) binding to anti-
DNA autoantibodies was achieved by an indirect band shift assay since thymine 
or poly(dT) cannot be visualized by ethidium intercalation. ROS-thymine and 
ROS-poly(dT) were allowed to interact with varying amounts of IgG for 2 hr at 
37°C and overnight at 4°C, followed by the addition of 200 bp DNA and 
incubation for 90 min at 37°C. The rationale behind this being that the unbound 
IgG would bind to nDNA which then could be visualized on agarose gel. It 
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Fig. 39. Elution profile of SLE IgG on Protein A Sepharose CL-4B 
affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% acrylamide gel. 
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Fig. 39. Elution profile of SLE IgG on Protein A Sepharose CL-4B 
affinity column. 
Inset: SDS-PAGE of purified IgG on 7.5% acrylamide gel. 
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Fig. 40. Band shift assay to show the binding of nDNA fragments ( -s ize 
200 bp) with SLE IgG. DNA fragments (0.2 /ig) were incubated 
with buffer (lane 1) and with 5, 10, 15 and 20 ^g IgG (lanes 2-5) 
for 2 hr at 37°C and overnight at 4°C. Electrophoresis was 
performed on 1% agarose for 2 hr at 30 mA. 
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Fig. 41. Band shift assay to show the binding of ROS-DNA with SLE IgG. 
ROS-DNA (2 ^g) was incubated with buffer (lane 1) and with 5, 
10, 20 and 30 /xg IgG (lanes 2-5) for 2 hr at 37°C and overnight at 
4°C. Electrophoresis was performed on 1 % agarose for 2 hr at 
30mA. 
I l l 
could be seen in Figure 42 that the fluorescent intensity of retarded bands was 
decreased and there was a lesser formation of high molecular weight immune 
complex(s) as in the case of nDNA-anti-DNA Ig interaction seen in Figure 40. 
The data clearly indicates the recognition of ROS-thymine by SLE anti-DNA 
autoantibodies. A similar retardation pattern was observed with ROS-po!y(dT) 
(Fig. 43), thus indicating the recognition of ROS-poly(dT) by naturally 
occurring anti-DNA autoantibodies. 
Dot Blot Assay 
Dot blot assay was performed to further confirm the binding of native 
DNA, ROS-DNA and ROS-poly(dT) visually (Fig. 44). As could be seen clearly 
from the photograph, a distinct spot appeared in all the three cases which was 
absent from the control. Thus showing further evidence for the binding of native 
DNA, ROS-DNA and ROS-poly(dT) with SLE autoantibodies. A similar test was 
performed with normal human serum which served as negative control wherein 
no reactivity was seen with the three antigens. 
Detect ion of Oxidative DNA Damage in SLE Patients using 
Monoclonal Antibody 
Genomic DNA was isolated from lymphocytes of SLE patients. The purity 
and concentration of the DNA preparations was ascertained by AJ^Q and AJ^Q 
measurements. The isolated DNA was found to be pure and had 260/280 ratio 
of 1.8-1.91. Oxidative damage to the human genome was immunochemically 
detected using monoclonal anti-ROS-DNA antibody as a probe by competition 
ELISA. Immune complex was made between isolated DNA and monoclonal 
antibody. It was found that out of the eight samples tested, four showed 
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Fig. 42. Binding of SLE IgG to ROS-thymine as analyzed by band shift 
assay. Modified thymine (10 fig) was incubated with 10, 15 and 20 
/xg IgG (lanes 3-5) for 2 hr at 37°C and overnight at 4°C. 
Thereafter 0.2 /ig nDNA (200 bp) was added and incubated for 90 
min at 37°C. Lane 1 contained nDNA alone, while lane 2 contained 
ROS-thymine and nDNA. Electrophoresis was performed on 1 % agarose 
for 2 hr at 30 mA. 
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Fig. 43. Band shift assay to ascertain the binding of SLE IgG to ROS-
poly(dT). Modified poly(dT) (1.5 /xg) was incubated with 10, 15 
and 20 fig IgG (lanes 3-5) for 2 hr at 37°C and overnight at 4°C. 
Thereafter 0.2 ng nDNA (200 bp) was added and incubated for 90 
min at 37°C. Lane 1 contained nDNA alone, while lane 2 contained 
10 /ig IgG and nDNA. Electrophoresis was performed on 1% 
agarose for 2 hr at 30 mA. 
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Fig. 44. Dot blot assay to confirm the binding of SLE autoantibodies to (a) 
native DNA (b) ROS-DNA and (c) ROS-poly(dT). Native DNA, 
ROS-DNA and ROS-poly(dT) (5 ng) were incubated with SLE 
serum (1:50 diluted) for 1 hr at 37°C, and subsequently assayed 
with anti-human Ig-HRP conjugate and 4-ch)oro-l-naphthol/ 
hydrogen peroxide substrate. 
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inhibitions greater than 50% i.e. 63.7%, 57.2%, 63.3% and 57.9% while only 
one showed a high inhibition of nearly 70%. The rest three exhibited low 
inhibition of 31.6%, 38.6% and 41.6% (Figs. 45 and 46). DNA isolated from 
lymphocytes of normal healthy individuals served as negative control. These 
results point out the likelihood of the presence of oxidative lesions in the DNA 
of SLE patients which are recognized by a monoclonal antibody having 
specificity for ROS-modified epitopes on nucleic acids. 
Immunofluorescence 
ROS-DNA was injected in rats and anti-ROS-DNA response was screened 
by direct binding ELISA. The immunofluorescence of the kidney sections of 
these rats revealed the deposition of immune complex in the glomeruli of rat 
kidney (Fig. 47). Kidney sections from control (unimmunized) rats did not show 
any fluorescence thereby suggesting the absence of immune complex deposition. 
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Fig.45. Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of SLE patients. The 
microtitre plates were coated with 400 bp ROS-DNA (2.5 ptg/ml). 
The curves ( O ) , ( ^ ) , ( • ) , ( C^ ) represent DNA samples from 
different individuals and ( k. ) represents DNA from normal, 
healthy individual. 
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Fig.46. Inhibition of anti-ROS-DNA monoclonal antibody binding to 400 bp 
ROS-DNA by DNA isolated from lymphocytes of SLE patients. The 
microtitre plates were coated with 400 bp ROS-DNA (2.5 /ig/ml). 
The curves ( O ), ( 3 ), ( • ), ( A ) represent DNA samples from 
different individuals and ( A ) represents DNA from normal, 
healthy individual. 
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Fig.47. Immune complex deposition seen in the glomeruli of rat immunized 
with ROS-DNA as detected by immunofluorescence using anti-rat 
IgG FITC conjugate. 
{M>UMW^ 
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It has long been hypothesized that the development of the immune system 
is triadic in nature. Useless cells are discarded, useful cells are retained while 
dangerous ones are destroyed or inactivated. Elimination or inactivation of 
emerging B cells reactive with membrane-bound self-antigens or soluble self-
antigens respectively, has also been documented (Goodnow, 1992). Similarly, T 
cells with receptors of dangerously high affinity/avidity are eliminated or 
inactivated by negative selection (Nossal, 1994; von Boehmer, 1994). Thus, 
through these editing processes, a state of self-tolerance is achieved. However, 
despite the recent acquisition of extensive information relating to the 
mechanisms of self-tolerance, our understanding of the mechanisms leading to 
pathogenic autoimmunity is still fragmentary and incomplete. Nevertheless, 
recent advances in this field have begun to assemble the missing pieces of the 
puzzle. A wide spectrum of human and animal diseases are wholly or partially 
attributable to autoimmunity (Theofilopoulos, 1993). This list continually 
expands as autoimmune mechanisms are implicated in widely diverse disorders 
such as urticaria, AIDS and even neuropsychological disorders (Theofilopoulos, 
1995). 
Systemic lupus erythematosus is a multi-system, inflammatory disorder 
characterized by the production of autoantibodies of multiple specificities, 
especially those reactive with intracellular proteins and nucleic acids. 
Circulating autoantibodies to dsDNA appear to correlate most uniquely with 
periods of clinical activity, especially renal complications (Aitcheson and Tan, 
1982). The active disease is characterized by the over production of pathogenic 
autoantibodies whereas the pre-clinical state is characterized by multiclonal B-
and T-cell activation, which releases cytokines and that creates an immuno-
stimulatory milieu that facilitates the subsequent anti-self responses (Klinman 
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and Steinberg, 1995). There is also evidence that DNA and anti-DNA antibodies 
comprise part of the circulating antigen-antibody complexes that precipitate in 
the renal glomeruli. The marked heterogeneity of SLE autoantibodies has been 
one of the impediments in understanding the disease. The immune abnormalities 
contributing to the development of systemic autoimmune disease in mice and 
humans are now being defined at the single-cell and molecular levels. The 
specific defects appear to be determined in different individuals by different 
genetic and environmental factors. Thus ' lupus' is not a disease but a syndrome 
with multiple different etiologies (Klinman and Steinberg, 1995) and 
expectations for a single etiological explanation may be unrealistic. There have 
been many theories proposed to explain the origin of autoimmune responses, for 
example a genetic predisposition, exaggerated random B-cell activity, cross-
reactivity between host and foreign antigens or modification of host proteins as 
a consequence of infection, inflammation, drug administration etc. (Radic and 
Weigert, 1994; Theofilopoulos, 1995). It has been suggested that while neither 
exogenous polyclonal B- or T-cell activators nor immunoregulatory disturbances 
appear to be satisfactory explanations, it is clear that development of overt 
autoimmune disease is highly dependent on a permissive genetic constitution 
(Theofilopoulos, 1995). 
An interesting and intriguing aspect of SLE is that while antibodies 
reactive with native double stranded DNA are characteristic of this chronic 
inflammatory disease, native DNA is a poor immunogen and hence the 
mechanism of anti-DNA antibody production is incompletely understood. On the 
other hand some synthetic homopolynucleotides, chemically modified DNA and 
denatured DNA are immunogenic. Also, double stranded RNA, RNA-DNA 
hybrid, left handed Z-DNA, triple helical RNA and DNA analogues that differ 
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from B-DNA have been found to be effective immunogens (Anderson et al., 
1988; Stollar, 1989). This conformational variance from B-form appears to be a 
prerequisite for the induction of an antibody response, although the reason for 
this is not clear (Braun and Lee, 1988). 
The damaging effects of reactive oxygen species (ROS), like superoxide 
anion radical (Oj*), hydrogen peroxide (HjOj) and hydroxyl radical ( 'OH) have 
gained considerable interest over the last few years (Fridovich, 1986; Halliwell, 
1987; Ballmer et al., 1994). Celluar DNA is damaged by oxygen free radicals 
generated during cellular respiration, cell injury, phagocytosis and exposure to 
environmental oxidants (Floyd et al., 1986; Fridovich, 1986; Kasai et al., 1986; 
Klebanoff, 1988; Breimer, 1990). It has been proposed that modification of 
DNA increases its immunogenicity and in inflammatory disease states such as 
SLE, reactive oxygen species (ROS) produced from phagocytic cells have been 
shown to modify DNA. Different procedures of ROS generation have been found 
to cause distinct and characteristic changes to DNA. A chemical modification 
of DNA using hydrogen peroxide, which reacts in the presence of a reducing 
agent and metal ions bound to DNA to produce the highly reactive hydroxyl 
radical, can cause DNA strand breaks, base damage (Massie et al., 1972) and 
conformational change (Allan et al., 1988). It has been observed that 
denaturation of double stranded DNA by ROS results in an increased binding of 
human anti-DNA autoantibodies (Blount et al., 1990). There seems to be an 
enormous binding diversity of lupus autoantibodies to a whole spectrum of 
modified nucleic acid conformers (Alam and AH, 1992; Alam et al., 1992; 1993; 
Arjumand and AH, 1994; Moinuddin and AH, 1994; Arjumand et al., 1995). 
Efforts to understand the origin and consequence of anti-ds-DNA antibodies are 
still in progress. It has also been reported earlier that DNA upon exposure to 
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254 nm light in the presence of hydrogen peroxide became highly immunogenic 
inducing high titre antibodies (Ara et al., 1992) which exhibited polyspecificity 
recognizing the modified polymer, native B-conformation, A and allied 
conformations (Ara and Ali, 1993). 
In the present study native DNA was modified by UV radiation (254 nm) 
in the presence of hydrogen peroxide. Also individual bases adenine, thymine 
and their respective homopolymers poly(dA), poly(dT) were similarly modified 
with ROS to understand the possible role of the modified conformers in the 
pathogenesis of SLE. The absorption of DNA decreased at 260 nm after 
treatment with H2O2 iand UV light. This observed hypochromicity could be 
attributed to the modification of the nitrogenous bases. However, treatment of 
DNA with hydrogen peroxide or UV light alone did not cause any significant 
change in the UV absorption profile. In the case of the bases adenine and 
thymine, modification with ROS caused a drastic change in their absorption 
spectra, with a loss of the characteristic peak at 260 nm. On the other, hand 
exposure of the polymers poly(dA) and poly(dT) to hydroxyl radical resulted in 
substantial decrease in UV absorbance at 260 nm. 
The thermal denaturation profile of native and ROS-DNA showed a net 
decrease of 13.5°C in the Tm value for the modified DNA as compared to its 
unmodified native conformer. This is primarily due to a structural alteration in 
DNA which occurs due to the simultaneous scission of the phosphodiester 
backbone and the generation of single strand breaks. 
The presence of single strand regions in DNA following treatment with 
ROS was further ascertained by alkaline sucrose gradient centrifugation. The 
sedimentation profile of ROS-DNA was distinct from that of unmodified native 
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DNA, which banded as a sharp symmetrical peak, while the modified DNA gave 
a broader peak indicating the generation of single strand breaks which causes 
changes in the nyoiecular weight and hence the diffused pattern. These data are 
compatible with earlier reports implicating hydroxyl radicals in the strand 
breakage (Meneghini and Hoffmann, 1980; Hoffmann et al., 1984). 
Hydroxyl radical appeared to generate sufficient distortions in DNA to act 
as substrates for nuclease SI (Slor and Lev, 1973; Yamasaki et al., 1977) and 
the present results with single strand specific nuclease SI are consistent with 
earlier findings. When native DNA complexed with hydrogen peroxide and 
exposed to UV light was subjected to nuclease SI digestion, the single strand 
regions in double stranded DNA were selectively removed as seen by the 
decreased intensity of the band. 
The hydroxyl radical was also found to produce DNA base modifications 
as revealed by ion-exchange chromatography. Thymine was found to be modified 
to the greatest extent followed by guanine which is consistent with earlier 
reports showing thymine to be the most susceptible to the modifying effects of 
hydroxyl radical (Hutchinson, 1985). In order to determine the participation of 
hydroxyl radical in causing alterations in thymine, its UV spectrum was 
compared to that of thymine dimer and was found to be clearly distinct from 
that of thymine dimer thereby suggesting that hydroxyl radical and not the UV 
radiation was responsible for the damage. 
Monoclonal antibodies generated against 400 bp modified DNA (Ashok, 
1996) were characterized for their fine antigenic specificity. These were found 
to be of IgGl isotype. The specificity of the purified anti-ROS-DNA antibodies 
for antigenic determinants on modified DNA was determined by direct binding 
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and inhibition ELISA. Direct binding ELISA demonstrated strong binding for 
ROS-DNA which was further confirmed by inhibition ELISA. A maximum of 
76,5% inhibition with the immunogen was observed and 4,4 ^g/mJ was required 
for 50% inhibition of antibody binding to antigen. The antibodies also showed 
an inhibition of 84% and 59.7% with native ROS-DNA and 200 bp ROS-DNA 
respectively, while the concentration required to obtain 50% inhibition was 3.0 
and 10.0 pig/ml respectively. When the individual bases were used as inhibitors 
of anti-ROS-DNA antibody binding to the antigen, it was found that ROS-
modified thymine was the most effective inhibitor followed by ROS-guanine 
while their unmodified forms were very poor inhibitors. On the other hand, the 
other two bases adenine and cytosine as well as their modified forms were not 
inhibitory. Also ROS-thymidine was inhibitory to the extent of 57.2% contrary 
to unmodified form. It was also observed that the ROS-modified homopolymer 
poly(dT) was an effective inhibitor of antibody binding to the antigen while its 
unmodified form was not. Poly(dA) and its modified form were non-inhibitory. 
These results clearly point out the preferential recognition of ROS-modified 
epitopes by the monoclonal antibodies having preference for thymine followed 
by guanine. Some degree of inhibition seen with native DNA and some synthetic 
polymers could be due to the sharing of antigenic determinants amongst ROS-
modified antigens and native DNA or synthetic polynucleotides. The logical 
candidate for this shared epitope is a sugar-phosphate backbone that occurs in 
all polynucleotides (Lafer et al., 1981; Rauch et al., 1985). 
The study of structure-function relationship of different amino acid 
residues of proteins has been successfully achieved by chemical modification of 
various amino acids (Cohen, 1970). Change in biological activity after chemical 
modification may be taken as an evidence of direct involvement of the modified 
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residue in catalytic function (Kaiser et al., 1985). The biological role of lysine 
residues in several enzymes has been demonstrated by chemical modification 
techniques. The acetylation of anti-ROS-DNA IgG was carried out to assess the 
role of lysine residues in the antigen binding characteristics of the protein. It 
was found that with an increase in acetylated lysine residues, there was a 
concomitant decrease in antibody binding, implying that such residues might be 
involved in the antigen binding site of the immunoglobulin molecule. 
Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease 
of unknown etiology. Sera of SLE patients contain a variety of autoantibodies 
of which a subset may be responsible for the array of chemical symptoms 
(Chastagner et al., 1994). Antibodies to double stranded DNA serve as an 
immunochemical marker for the diagnosis of SLE. However, native DNA is a 
poor immunogen and rarely induces antibodijes in experimental animals. It has 
been reported that DNA after exposure to ROS presents a more discriminating 
antigen for the binding of SLE autoantibodies (Blount et al., 1989; 1990). Thus 
it appears that ROS modification exposes epitopes on DNA that are recognized 
by circulating anti-DNA antibodies in SLE sera. 
In the present study, anti-DNA antibodies from SLE sera were tested for 
their binding with various nucleic acids. It was found that appreciable binding 
was seen with ROS-DNA in eight different SLE sera and the concentration 
required to obtain 50% inhibition was found to be more for native DNA 
compared to ROS-modified DNA in six out of eight cases. Furthermore, in 
order to investigate the epitope(s) involved in anti-DNA autoantibody production 
in SLE, the individual base thymine modified with ROS was used as an inhibitor 
as ROS-thymine exhibited maximum binding with the monoclonal antibodies out 
of all the four bases tested. Interestingly, a high to moderate level of inhibition 
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was observed with almost all of the SLE sera tested with ROS-thymine as 
inhibitor. The homopolymer poly(dT) modified with ROS also exhibited around 
50% or more inhibition in five out of the eight sera. The binding was further 
confirmed by a band shift and dot blot assay. 
These results point out similar binding characteristics with the induced 
antibodies and naturally occurring SLE autoantibodies showing preference for 
ROS-modified epitopes. The likelihood of thymine modification as a result of 
ROS attack on DNA by phagocytic cells in SLE might be the trigger for the 
induction of circulating antibodies generated against modified epitope but cross-
reacting with native DNA. The unusual DNA conformations are mostly 
immunogenic as they exist only transiently in cells and are therefore not subject 
to tolerance. Therefore, when administered to animals in a stabilized form, they 
can stimulate antibody production. Inhibition studies with unmodified thymine/ 
adenine and ROS-modified adenine failed to show appreciable binding to SLE 
autoantibodies. It appears that pathogenic anti-DNA autoantibodies are 
generated by some altered conformational epitopes on nucleic acids. 
The role of oxidative damage has been suggested in autoimmune diseases 
including rheumatoid arthritis and systemic lupus erythematosus (Loft and 
Poulsen, 1996). Lymphocytes isolated from patients suffering from either 
disease contain increased levels of 8-oxo-dG in the DNA. ROS has been found 
to induce the formation of 8-oxo-dG and GC to AT transitions (Epe, 1991; 
Emmerit et al., 1995) and 8-oxo-dG mispairs mainly with adenine (Shibutani et 
al., 1991; Kamiya et al., 1995b). Therefore, oxidatively modified DNA having 
altered base(s) and conformational difference from B-form trigger immune 
response and the antibodies thus generated represent circulating anti-DNA 
antibodies in SLE patients. Accordingly, SLE patients suffer from an increased 
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rate of oxidative DNA damage and are also deficient in repair process. This may 
contribute to the pathogenesis of SLE as well as increased chances of malignant 
diseases in these patients (Lunec et al., 1994). In this study the presence of 
oxidative damaged lesions in SLE was detected using anti-ROS-DNA monoclonal 
antibody as a probe. Five out of the eight DNA samples of SLE patients tested 
showed a high inhibition of monoclonal antibody binding to ROS-DNA, while 
no appreciable binding was seen with DNA isolated from normal, healthy 
individuals. The data indicates the presence of oxidative lesions in the DNA of 
these patients that are being effectively recognized by the monoclonal antibody. 
ROS-DNA induced high titre antibodies in rats. Kidney sections of these 
rats were used to detect the deposition of immune complexes in the glomerulus. 
Immunofluorescence revealed the accumulation of immune complexes in the 
glomeruli of the kidney as evident by an apple green fluorescence. This could 
be correlated to the finding that lupus nephritis is a prototype of immune 
complex mediated disease (Tsai et al., 1992). Deposition of the complexes 
between DNA and antibodies to DNA in kidneys has been considered to 
elucidate the inflammatory reaction in lupus nephritis. 
Based on the above studies the following conclusions can be drawn. 
1. DNA modified with UV light (254 nm) in the presence of hydrogen 
peroxide resulted in the formation of single strand breaks and modification 
of DNA bases. 
2. Thymine was the major base modified with ROS, followed by guanine. 
3. The monoclonal antibodies against ROS-modified DNA were found to be 
of IgGl subtype. 
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4. The monoclonal antibodies were found to be specific towards ROS-modified 
epitopes with some degree of binding seen with native DNA suggesting the 
presence of certain common epitopes on native and modified polymer. 
5. Lysine residues of monoclonal antibodies were found to be involved in 
antigen recognition. 
6. SLE anti-DNA autoantibodies showed a preferential binding for ROS-DNA 
compared to its native form. 
7. ROS-thymine and ROS-poly(dT) exhibited high degree of binding to SLE 
autoantibodies. 
8. Almost identical antigenic specificity of the induced anti-ROS-DNA 
antibodies and SLE autoantibodies as well as high binding of these 
antibodies with ROS-thymine suggests that ROS-thymine could be the major 
modified epitope, against which antibodies are produced in SLE which are 
cross-reating with native DNA. 
9. Monoclonal antibody used as a probe showed effective recognition of 
oxidative damage to DNA in SLE patients. 
10. Immune complex deposition in the glomeruli of kidney of ROS-modified 
DNA immunized rat was observed. 

129 
Adams, D. (1996) Immunol. Today 17, 300-302. 
Adams, R.L.P., Budon, R.H., Campbell, A.M., Leader, D.P. and Smellie, 
R.M.S. (1981) In: The Biochemistry of NucJeic Acids, 9th Ed. pp.24. 
Chapman and Hall (London) 
Adelman, D.C., Saltiel, E. and Klinenberg, J. (1986) Semin. Arth. Rheum. 15, 
185-199. 
Aitcheson, C. and Tan, E. (1982) Antinuclear antibodies. In: Scientific Basis 
of Rheumatology (Panayi, G.S. Ed.), pp.96. Churchill Livingstone, 
Edinburgh. 
Alam, K., Ali, A. and AH, R. (1993) FEBS Lett. 319, 66-70. 
Alam, K. and Ali, R. (1992) Biochem Int. 26, 597-605. 
Alam, K., Islam, N., Hasan. R., Ali, A. and Ali, R. (1992) Microbiol. 
Immunol. 36, 1003-1007. 
Alarcon-Segovia, D., Llorente, L., Fishbein, E. and Diaz-Jouanen, E. (1982) 
Arth. Rheum. 25, 304-317. 
Alarcon-Segovia, D., Ruiz-Arguelles, A. and Llorente, L. (1996) Immunol. 
Today 17, 163-164. 
Ali, A., Hasan, R. and Ali, R. (1991) Biochem. Int. 23, 111-118. 
Ali, R., DerSimonian, H. and Stollar, B.D. (1985) Mol. Immunol. 22, 1415-
1422. 
Ali, R. and Sauerbier, W. (1978) Biophys. J. 22, 393-411. 
Allan, I.M., Vaughan, A.T.M., Milner, A.E., Lunec, J. and Bacon, P.A. (1988) 
Br. J. Cancer 58, 34-37. 
Ames, B.N. (1983) Science 221, 1256-1264. 
Ames, B.N., Cathcart, R., Schwiers, E. and Hochstein, P. (1981) Proc. Natl. 
Acad. Sci. (U.S.A.) 78, 6858-6862. 
130 
Anderson, W.F., Cygler, M., Braun, R.P. and Lee, J.S. (1988) BioEssays 8, 
69-74. 
Aotsuka, S., Okawa, M., Ikebe, K. and Yokohari, R. (1979) J. Immunol. 
Methods 28, 149-162. 
Appel, G. (1991) Kidney Int. 39, 169-183. 
Ara, J., Ali, A. and All, R. (1992) Immunol. Invest. 21, 553-563. 
Ara, J. and Ali, R. (1992) Immunol. Lett. 34, 195-200. 
Ara, J. and Ali, R. (1993) Clin. Exp. Immunol. 94, 134-139. 
Arjumand, S. and Ali, A. (1994) Microbiol. Immunol. 38(3), 239-243. 
Arjumand, S., Arif, Z., Ali, A. and Ali, R. (1995) Immunol. Lett. 48, 215-
219. 
Arnett, F.C. (1992) Clin. Exp. Immunol. 94, 134-139. 
Arnett, F . C , Edworthy, S.M., Bloch, D.A., Mc Shane, D.J., Fries, J .F . , 
Cooper, N.S., Healy, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S.. 
Medsger, T.A., Mitchell, D.M., Neustadt, D.H., Finals, R.S., Schaller, 
J.G., Sharp, J.T., Wilder, R.L. and Hunder, G.G. (1988) Arth. Rheum. 
31, 315-324. 
Arnott, S., Chandrasekaran, R., Hukins, D.W.L., Smith, P.J. and Watts, L. 
(1974) J. Mol. Biol. 88, 523-533. 
Arroyo, C M . , Wade, J. V., Ichimori, K. and Nakazawa, H. (1994) Chem. BioL 
Interact. 91, 29-38. 
Ashok, B.T. (1996) Ph.D. Thesis, Department of Biochemistry Faculty of 
Medicine. Aligarh Muslim University, Aligarh. 
Attman, P.O. and Alaupovic, P. (1990) Am. J. Nephrol. 10 (suppi), 69-75. 
Avery, O.T., MacLeod, C M . , and McCarty, M. (1944) J. Exp. Med. 79, 137-
158. 
131 
Bach, J .F. , Fracchia, G.N. and Chatenoud, L. (1993) Immunol. Today 14, 421-
425. 
Balentine, J.D. (1982) Pathology of Oxygen Toxicity. Academic Press, New 
York. 
Ballmer, P.E., Reinhart, W.H. and Gey, K.F. (1994) Ther-Umsch 51, 467-474. 
Bashir, S., Harris, G., Denman, M.A., Blake, D.R. and Winyard, P.G. (1993) 
Ann. Rheum. Dis. 52, 659-666. 
Bass, F . , Bikker, H., Van Ommen, G.J.B. and de Vijlder, J.J.M. (1984) Hum. 
Genet. 67, 301-305. 
Bias, W.B., Reveille, J.D., Beaty, T.H., Meyers, D.A.'and Arnett, F.C. (1986) 
Am. J. Human Genet. 39, 584-602. 
Blank, M., Ben-Bassat, M. and Shoenfeld, Y. (1992) Arth. Rheum. 35, 1350-
1355. 
Blix, U., Hand, C.N. and Stacey, M. (1954) Br. J. Exp. Pathol. 35, 241. 
Blount, S., Griffiths, H.R., Emery, P. and Lunec, J. (1990) Clin. Exp. 
Immunol. 81, 384-389. 
Blount, S., Griffths, H.R. and Lunec, J. (1989) FEBS Lett. 245, 100-104. 
Bottazzo, G.F., Pujol-Borrel, R. and Hanafusa, T. (1983) Lancet 2, 1115-1119. 
Braun, R.P. and Lee, J.S. (1988) J. Immunol. 141, 2084-2089. 
Breimer, L.H. (1990) Mol. Carcinogenesis 3, 188-197. 
Bruneau, C. and Benveniste, J. (1979) J. Clin. Invest. 64, 191-198. 
Burden, R.H., Gill, V., Boyd, PA. and Rahim, RA. (1996) FEBS Lett. 383, 
150-154. 
Burnet, F.M. (1959a) The Clonal Selection Theory of Acquired Immunity, 
Cambridge University Press. 
132 
Burnet, F.M. (1959b) Br. Med. J. 2, 645-650. 
Burnet, F.M. (1959c) Br. Med. J. 2, 720-725. 
Burton, K. (1956) Biochem. J. 62, 315-323. 
Buxton, G.V., Greenstock, C.L., Helman, W.P. and Ross, A.B. (1988) Phys. 
Chem. Ref. Data 17, 513-886. 
Cannon-Carlson, S.V., Gokhale, H. and Teebor, G.W. (1989) J. Biol. Chem. 
264, 13306-13312. 
Carlsten, H., Tarakowski, A., Holmdahl, R. and Nilsson, L.A. (1990) Clin. 
Exp. Immunol. 80, 467-473. 
Carpenter, D.F., Steinberg, A.D., Schur, P.H. and Talal, N. (1970) Lab. 
Invest. 23, 628-634. 
Carroll, P., Stafford, D., Schwartz, R.S. and StoIIar, B.D. (1985) J. Immunol. 
135, 1086-1090. 
Chastagner, P., Demaison, C , Theze, J. and Zouali, M. (1994) Scand. J. 
Immunol. 39, 165-178. 
Cohen, L.A. (1970) In: The Enzymes (Boyr, P.D. Ed.) Vol.1, pp. 147-211. 
Academic Press, New York. 
Counihan, K.A., Vertosick, F.T. and Kelly, R.H. (1991) Immunol. Invest. 20, 
311-331. 
Czapski, G. (1984) Isr. J. Chem. 24, 29-32. 
Das, K.C. and Misra, H.P. (1992) Mol. Cell. Biochem. 115, 179-185. 
Demple, B. and Harrison, L. (1994) Annu. Rev. Biochem. 63, 915-948. 
Demple, B. and Linn, S. (1980) Nature 287, 203-208. 
Deodhar, S.D. (1992) Clin. Biochem. 25, 181-185. 
133 
Dickerson, R.E., Drew, H.R., Conner, B.N., Wing, R.M., Fratini, A.V. and 
Kopka, M.L. (1982) Science 216, 475-485. 
Dizdaroglu, M. (1992) Mutat. Res. 275, 331-342. 
Drake, C.G., Rozzo, S.J., Vyse, T.J., Palmer, E. and Kotzin, B.L. (1995) 
Immunol. Rev. 144, 51-74. 
Drew, H.R., McCall-M.J. and Calladine, C.R. (1988) Annu. Rev. Cell Biol. 4, 
1-20. 
Driggers, W.J., Grishko, V.I., LeDoux, S.P. and Wilson, G.L. (1996) Cancer 
Res. 56, 1262-1266. 
Druet, P. (1992) J. Immunol. Meth. 150, 177-184. 
Duthie, S.J., Ma, A., Ross, M.A. and Collins, A.R. (1996) Cancer Res. 56, 
1291-1295. 
Dziarski, R. (1988) Immunol. Today 9, 340-342. 
Ehrenstein, M.R., Longhurst, C M . , Latchman, D.S. and Isenberg, D.A. (1994) 
J. Clin. Invest. 93, 1787-1797. 
Emlen, W., Pisetsky, D.S. and Taylor, R.P. (1986) Arth. Rheum. 29, 1417-
1426. 
Emmerit, S., Epe, B., Saha-MoUer, C.R., Adam, W. and Runger, T.M. (1995) 
Phoiochem. Photobiol. 61, 136-141. 
Epe, B. (1991) Chem. Biol. Interact. 80, 239-260. 
Farhataziz and Rodgers, M.A.J. (Eds.), (1987) In: Radiation Chemistry, VCH, 
New York. 
Feldman, M.D., Huston, D.P., Karsh, J., Balow, J.E. and Steinberg, A.D. 
(1982) J. Rheumatol. 9, 52-58. 
Fenton, H.J.H. (1894) Chem. Soc. J. 65, 899-910. 
134 
Floyd, R.A., Watson, J.J., Harris, J., West., M. and Wong, P.K. (1986) 
Biochem. Biophys. Res. Commun. 137, 841-846. 
Frank-Kamenetskii, M.D. (1990) DNA supercoiling and unusual structures. In: 
DNA Topology and its Biological Effects (Cozzarelli, N.R. and Wang, J.C. 
Eds.), pp. 185-215. Cold Spring Harbor Laboratory Press. Cold Spring 
Harbor, New York. 
Fredriksen, K., Osei, A., Sundsfjord, A., Traavik, T. and Rekvig, O.P. (1994) 
Eur. J. Immunol 24, 66-70. 
Fredriksen, K., Skogsholm, A., Flaegstad, T., Traavik, T. and Rekvig, O.P. 
(1993) Scand. J. Immunol. 38, 401-406. 
Fridovich, I. (1975) Annu. Rev. Biochem. 44, 147-159. 
Fridovich, I. (1978a) Science 201, 875-880. 
Fridovich, I. (1978b) Annu. Rev. Biochem. 47, 147-152. 
Fridovich, I. (1986) Arch. Biochem. Biophys. 247, 1-11. 
Gates, F.T. and Linn, S. (1977) J. Biol. Chem. 252, 2802-2807. 
Gilbert, D.L. (Ed.), (1981) In: Oxygen and Living Processes; An 
Interdisciplinary Approach. Springer Verlag, New York. 
Gilkeson, G.S., Pippen, A.M.M. and Pisetsky, D.S. (1995) J. Clin. Invest. 95, 
1398-1402. 
Gilkeson, G.S., Pritchard, J.P. and Pisetsky, D.S. (1991) Clin. Immunol. 
Immunopathol. 59, 288-300. 
Goldstein, S. and Czapski, G. (1986) J. Am. Chem. Soc. 108, 2244-2250. 
Goodnow, C.C. (1992) Annu. Rev. Immunol. 10, 489-518. 
Habeeb, A.F.S.A. (1966) Anal. Biochem. 14, 328-335. 
Haber, F. and Weiss, J. (1934) Proc. Roy. Soc. Lond. Ser. A. 147, 332-351. 
135 
Hailiwell, B. (1978) FEBS Lett. 92, 321-326. 
Halliwell, B. (1981) In: Age Pigments (Sohal, R.S., Ed.), pp. 1-62. Elsevier, 
Amsterdam. 
Halliwell, B. (1982) Cell Biol. Int. Rep. 6, 529-542. 
Halliwell, B. (1987) FASEB J. 1, 358-364. 
Halliwell, B. and Gutteridge, J.M.C. (1985) In: Free radicals in Biology and 
Medicine. Clarendon Press, Oxford, London. 
Halliwell, B. and Gutteridge, J.M.C. (1986) Arch. Biochem. Biophys. 246, 501-
514. 
Halliwell, B. and Gutteridge, J.M.C. (1989) In: Free radicals in Biology and 
Medicine, 2nd edition. Clarendon Press, Oxford, London. 
Hammers, M.N. and Roos, D. (1985) In: Oxidative Stress (Sies, H. Ed.), pp. 
351-381. Academic Press, London. 
Hart, E.J. (1972) Radiat. Res. Rev. 3, 285-304. 
Hasan, R., Ali, A. and Ali, R. (1991) Biochim. Biophys. Acta 1073. 509-513. 
Hasan, R. and Ali, R. (1990) Biochem. Int. 20, 1077-1088. 
Haskowa, V., Hilgert, I., Hrubesowa, M., and Pokorna, Z.(1959) Folio Biol. 
(Prague) 5, 304. 
Herbaczynska-Cendro, K., Wartanowicz, M., Panczenko-Kresowska, B., Cedro, 
K., Klosiewicz-Wasek, B. and Wasek, W. (1994) Eur. J. Clin. Invest. 24, 
316-319. 
Hershey, A.D., and Chase, M. (1952) J. Gen. Physiol. 36, 39-56. 
Hochberg, M.C. (1987) J. Rheumatol. 14, 867-869. 
Hoffmann, M.E., Mello-Filho, A.C. and Meneghini, R. (1984) Biochim. 
Biophys. Acta 781, 234-238. 
136 
Hoffman, M.E. and Meneghini, R. (1979). Photochem. Photobiol. 29. 299-303. 
Huang, Y.P., Perrin, L.H., Miescher, P.A. and Zubler, R.H. (1988) J. 
Immunol. 141, 827-833. 
Hutchinson, F. (1985) Prog. Nucleic Acid Res. Mol. Biol. 32, 115-154. 
Icho, T., Kojima, S., Shinohara, N., Kajimara, Y., Kitabat^ke, K. and Kubota, 
K. (1993) Biochem. Pharmacol. 45, 1953-1958. 
Imlay, J.A. and Linn, S. (1988) Science 240, 1302-1309. 
Isenberg, D.A., Ehrenstein, M.R., Longhurst C. and Kalsi, J.K. (1994) Arth. 
Rheum. 37, 169-180. 
Isenberg, D.A. and Shoenfeld, Y. (1987) Immunol. Today 8, 279-281. 
Jacob, L. and Viard, J.P. (1992). Eur. J. Med. 1, 425-431. 
Jaworski, A., Hsieh, W.T., Blaho, J.A., Larson, J.E. and Wells, R.D. (1987) 
Science 238, 773-777. 
Jerne, N.K. (1955) Proc. Natl. Acad. Sci. (U.S.A.) 41, 849-853. 
Joenje, H. (1989) Mutat. Res. 219, 193-208. 
Juarez, C , Vila, J.L., Agusti, M., Gelpi, C , Amengual, M.J., Cardona, S. 
and Rodriguez-Sanchez, J.L. (1994) Clin. Immunol. Immunopathol. 72, 
248-254. 
Kaiser, E.T., Lawrence, D.S. and Rokita, S.E. (1985) Annu. Rev. Biochem. 
54, 565-595. 
Kamiya, H., Miura, H., Kamiya, N.M., Ishikawa, H., Sakaguchi, T., Inoue, 
H., Sasaki, T., Masutani, C , Hanaoka, P., Nishimura, S. and Ohtsuka, 
E. (1995a) Nucleic Acids Res. 23, 2893-2899. 
Kamiya, H., Murata-Kamiya, N., Fujimora, M., Kido, K., Inoue, H., 
Nishimura, S., Masutani, C , Hanaok, F. and Ohtsuka, E. (1995b) Jpn. J. 
Cancer Res. 86, 270-276. 
137 
Kaplan, D., Ginzler, E.M. and Feldman, J. (1992) Arth. Rheum. 35, 423-428. 
Kardost, R.R.P., Billing, P.A. and Voss, E.W., Jr. (1982) Mol. Immunol. 19, 
645-650. 
Karounos, D.G., Grudier, J.P. and Pisetsky, D.S. (1988) J. Immunol. 140, 451-
455. 
Kasai, H., Grain, P.P. , Kuchino, Y., Nishimura, S., Ootsuyama, A. and 
Tanooka, H. (1986) Carcinogenesis 7, 1849-1851. 
Kasprzak, K.S. (1995) Cancer Invest. 13, 411-430. 
Kennard, O. (1983) In: Nucleic acids; The Vectors of Life (Pullman, B. and 
Jortner, J. Eds.), pp. 33-48. Reidel Publishing Company, Dordrecht. 
Klebanoff, S.J. (1988) In: Inflammation; Basic Principles and Clinical 
Correlates (Gallin, J.I . , Goldstein, I.M. and Snyderman, R. Eds.), pp. 
391-444. Raven Press, New York. 
Klinman, D.M., Eisenberg, R.A. and Steinberg, A.D. (1990) J. Immunol. 144, 
506-511. 
Klinman D.M., Shirai, A., Conova, J. and Steinberg, A.D. (1994) Eur. J. 
Immunol. 24, 53-58. 
Klinman, D.M. and Steinberg, A.D. (1995) Immunol. Rev. 144, 157-193. 
Knight, J.A. (1995) Ann. Clin. Lab. Sci. 25, 111-121. 
Kohler, G. and Milstein, C. (1975) Nature 256, 495-497. 
Kotzin, B.L. and O'Dell, J.R. (1994) Systemic lupus erythematosus. In: 
Samter's Immunological Diseases (Frank, M.M., Austin, K.F., Claman, 
H.N. and Unanue, E.R., Eds.), pp.667. Boston, Little Brown and Co. 
Krieg, A.M. (1995) J. Clin. Immunol. 15, 284-292. 
Kumar, A., Malaviya, A.N., Singh, R.R., Singh, Y.N., Adya, C M . and 
Kakkar, R. (1992) Rheumatol. Int. 12, 107-109. 
138 
Kurata, N. and Tan, E.M. (1976) Arth. Rheum. 19, 574-580. 
Kurschner, C , Garotta, G. and Dembic, Z. (1992a) J. Biol. Chem. 267, 9354-
9360. 
Kurschner, C., Ozmen, L., Garotta, G. and Dembic, Z. (1992b) J. Immunol 
149, 4096-4100. 
Laemmli, U.K. (1970) Nature 227, 680-685. 
Lafer, E.M., Rauch, J., Andrzejewski, C , Mudd, D., Furie, B.C., Furie, B., 
Schwartz, R.S. and Stollar, B.D. (1981) J. Exp. Med. 153, 897-909. 
Lafer, E.M. and Stollar B.D. (1984) J. Biomol. Struct. Dyn. 2, 487-494. 
Lahita, R.G. (1992) Clin. Immunol. Immunopathol. 63, 17-18. 
Lahita, R.G. and Kunkel, H.G. (1984) Arth. Rheum. 27, S 65. 
Lambert, P.H. and Dixon, F.J. (1968) J. Exp. Med. 127, 507-522. 
Lambert, P.H. and Dixon, F.J. (1970) Clin. Exp. Immunol. 6, 829-839. 
Levine, L. and Stollar, B.D. (1968) Prog. Allergy 12, 161. 
Levine, L. and van Vunakis, H. (1967) In: Antibodies to Biologically Active 
Molecules (Cinader, B. Ed.), pp. 25-60. Pergamon, Oxford. 
Loft, S. and Poulsen, H.E. (1996) J. Mol. Med. 74, 297-312. 
Lowry, O.H., Rosenberg, N.J., Farr, A.L. and Randall, R.J. (1951) J. Biol. 
Chem. 193, 265-275. 
Lunec, J., Herbert, K., Blount, S., Griffiths, H.R. and Emery, P. (1994) FEBS 
Lett. 348, 131-138. 
Madaio, M.P., Hodder, S., Schwartz, R.S. and Stollar, B.D. (1984) J. 
Immunol. 132, 872-876. 
Malins, D.C. and Haimanot, R. (1990) Biochem. Biophys. Res. Commun. 173, 
614-619. 
139 
Massie, H.R., Samis, H.V. and Baird, M.B. (1972) Biochim. Biophys. Acta 
272, 539-548. 
Matsuo, N. and Ross, P.M. (1987) Biochemistry 26, 2001-2009. 
McCord, J.M. and Day, E.D. (1978) FEBS Lett. 86, 139-142. 
Mellins, E.D. (1992) J. Rheumatol. 19, 63-69. 
Meneghini, R. and Hoffmann, M.E. (1980) Biochim. Biophys. Acta 608, 167-
173. 
Meneghini, R. and Martins, E.L. (1993) In: DNA and Free Radicals (Halliwell, 
B. and Aruoma, O.I. Eds.), pp.83-93. Ellis Horwood, Chichester. 
Miller, K.B. and Schwartz, R.S. (1982) Adv. Intern. Med. 27, 281-313. 
Moinuddin and Ali, A. (1994) Lupus 3, 43-46. 
Moorhouse, C.P., Halliwell, B., Grootveld, W. and Gutteridge, J.M.C. (1985) 
Biochim. Biophys. Acta 843, 265-268. 
Morimoto, C , Steinberg, A.D., Letvin, N.L., Hagen, M., Talceuchi, T., Daley, 
J., Levine, H. and Schlossman, S.F. (1987) J. Clin. Invest. 79, 762-768. 
Morris, J.G. (1976) J. Appl. Bacteriol. 40, 229-239. 
Muller, F. (1992) Free Rad. Biol. Med. 13, 651-657. 
Nackerdien, Z., Kasprzak, K.S., Roa, G., Halliwell, B. and Dizdaroglu, M. 
(1991) Cancer Res. 51, 5837-5842. 
Nackerdien, Z., Olinski, R. and Dizdaroglu, M. (1992) Free Rad. Res. 
Commun. 16, 259-273. 
Nahon, E., Lacour, F. and Michelson, A.M. (1967) C-R- Acad-Sci-Hebd-
Seances-Acad-Sci-D. 264, 515-518. 
Nossal, G.J.V. (1994) Cell 76, 229-239 
140 
Olinski, R., Zastawny, T., Budzbon, J., Skokowski, J., Zegarski, W. and 
Dizdaroglu, M. (1992) FEES Lett. 309, 193-198. 
Omdal, R., Selseth, B., Klow, N.E., Husby, G. and Mellgren, S.I. (1989) 
Scand. J. Rheumatol. 18, 283-289. 
Oshino, N., Chance B., Sies, H. and Bucher, J. (1973) Arch. Biochem. 
Biophys. 154, 117-131. 
Ozmen, L., Roman, D., Fountoulakis, M., Schmid, G., Ryffel, B. and Garotta, 
G. (1995) Eur. J. Immunol. 25, 6-12. 
Pechenaya, V.l. (1993) Biopolymers 33, 37-44. 
Petterson, T., Pukkala, E., Teppo, L. and Friman, C. (1992) Ann. Rheumatol. 
Dis. 51, 437-439. 
Pietrasanta, L.I., Schaper, A. and Jovin, T.M. (1994) Nucleic. Acids Res. 22, 
3288-3292. 
Pisetsky, D.S. (1996) J. Immunol. 156, 421-423. 
Plescia, O.J., Braun, W. and Palczuk, N.C. (1964) Proc. Natl. Acad. Sci. 
(U.S.A.) 52, 279-285. 
Pollard, K.M., Jones, J.E., Tan, E.M., Theofilopoulos, A.N., Dixon, F.J. and 
Rubin, R.L. (1986) Clin. Immunol. Immunopathol. 40, 197-208. 
Porter, R. and Whelan, J. (Eds.), (1983) Biology of Vitamin E. Ciba 
Symposium 101 (Pitman, Bath, U.K.). 
Radic, M.Z. and Weigert, M. (1994) Annu. Rev. Immunol. 12, 487-520. 
Radman, M. (1976) J. Biol. Chem. 251, 1438-1445. 
Rauch, J., Massicott, H. and Tannenbaum, H. (1985) J. Immunol. 134, 180-
186. 
Raz, E., Ben-Bassat, H., Davidi, T., Shlomai, Z. and Eilat, D. (1993) Eur. J. 
Immunol. 23, 383-390. 
141 
Reichlin, M., Martin, A., Taylor-Albert, E., Tsuzaka, K., Zhang, W., 
Reichlin, M.W., Koren, E., Ebling, P.M., Tsao, B. and Hahn, B.H. 
(1994) J. Clin. Invest. 93, 443-449. 
Rich, A., Nordheim, A. and Wang, A.H.J. (1984) Annu. Rev. Biochem. 53, 
791-846. 
Richter, C. (1992) Mutat. Res. 275, 249-255. 
Riordan, J .F. and Vallee, B.L. (1972) Meth. Enzymol. 25, 500-506. 
Rowley, D.A. and Halliwell, B. (1983) Arch. Biochem. Biophys. 225, 279-284 
Sage, E. (1993) Photochem. Photobiol. 57, 163-174. 
Sancar, A. and Sancar, G.B. (1988) Annu. Rev. Biochem. 57, 29-67. 
Sancar, A. and Tang, M.S. (1993) Photochem. Photobiol. 57, 905-921. 
Sarma, M.H., Gupta, G. and Sarma, R.H. (1986) Biochemistry 25, 3659-3665. 
Schneider, J .E., Browning, M.M., Zhu, X., Eneff, K.L. and Floyd, R.A. 
(1989) Mutat. Res. 214, 23-31. 
Schulte-Frohlinde, D. and von Sonntag, C. (1985) In: Oxidative Stress (Sies, 
H. Ed.), pp. 11-40. Academic Press, London. 
Schwartz, R.S. and Stollar, B.D. (1985) J. Clin. Invest. 75, 321-327. 
Seaman, E., Levine, L. and Van Vunakis, H. (1965) Biochemistry 4, 2091. 
Segal, A.W. (1989) The respiratory burst in monocytes and macrophages. In: 
Human Monocytes (Zembala, M. and Asherson, G.L. Eds.), pp. 89-100. 
Academic Press, London. 
Setlow, P. (1992) Mol. Microbiol. 6, 563-567. 
Shibutani, S., Takeshita, M. and Grollman, A.P. (1991) Nature 349, 431-434. 
Shivakumar, S., Tsokos, G.C. and Datta, S.K. (1989) J. Immunol. 143, 103-
112. 
142 
Shoenfeld, Y. and Isenberg, D. (1989) Immunol. Today 10, 123-126. 
Shoenfeld, Y., Rauch, J., Massicotte, H., Datta, S.K., Andre-Schwartz, J., 
Stellar, B.D. and Schwartz, R.S. (1983) N. Engl. J. Med. 308, 414-420. 
Slor, H. and Lev, T. (1973) Biochim. Biophys. Acta 312, 637-644. 
Steinberg, A.D. (1992) Clin. Immunol. Immunopathol. 63, 19-22. 
Steinberg, A.D. (1994) Clin. Immunol. Immunopathol. 72, 171-176. 
Steinberg, A.D., Baron, S. and Talal, N. (1969) Proc. Natl. Acad. Sci. 
(U.S.A.) 63, 1102-1107. 
Stoewe, R. and Prutz, W.A. (1987) Free Rad. Biol. Med. 3, 97-105. 
Stollar, B.D. (1970) Science 169, 609-611. 
Stollar, B.D. (1986) CRC Crit. Rev. Biochem. 20, 1-36. 
Stollar, B.D. (1989) Int. Rev. Immunol. 5, 1-22. 
Streller, B.L. (1986) Exp. Gerontol. 21, 283-319. 
Strniste, G.F. and Wallace, S.S. (1975) Proc. Natl. Acad. Sci. (U.S.A.) 72, 
1997-2001. 
Suenaga, R. and Abdou, N.l. (1992) Lupus 1, 363-368. 
Suzuki, Y.J., Tsuchiya, M. and Packer, L. (1991) Free Rad. Res. Commun. 15, 
255-263. 
Tachon, P. (1989) Free. Rad. Res. Commun. 7, 1-10. 
Talal, N. (1979) N. Engl. J. Med. 301, 838-839. 
Talal, N. (1989) Clin. Immunol. Immunopathol. 53, 1-3. 
Talal, N. and Ahmad, S.A.L. (1987) J. Rheumatol. 14, 191-193. 
143 
Tan, P.L.J., Pang, G.T.M., Wilson, J.D. and Cullinane, G. (1980) J. 
Rheumatol. 7, 807-813. 
Teebor, G.W., Frenkel, K. and Goldstein, S. (1984) Proc. Natl. Acad. Sci. 
(U.S.A.) 81, 318-321. 
Theofilopoulos, A.N. (1993) In: The Molecular Pathology of Autoimmune 
Diseases (Bona, C , Siminovitch, K.A., Zanetti, M. and Theofilopoulos, 
A.N. Eds.), pp. 1-12. Harwood Academic Publishers. 
Theofilopoulos, A.N. (1995) Immunol. Today 16, 90-98. 
Theofilopoulos, A.N. and Dixon, F.J. (1985) Adv. Immunol. 37, 269-390. 
Thoburn, R., Koffler, D. and Kunkel, H.G. (1971) Proc. Soc. Exp. Biol. Med. 
136, 711-714. 
Travers, A.A. (1989) Annu. Rev. Biochem. 58, 427-452. 
Trumbore, C.N., Myers, Y.N., Hyde, C.K., Hudson, R.D., Rhodes, C.N. and 
Masselink, J.K. (1994) Int. J. Radiat. Biol. 66, 479-483. 
Tsai, C.Y., Wu, T.H., Sun, K.H. and Yu, C.L. (1992) Ann. Rheumatol. Dis. 
51, 162-167. 
Viard, J .P. , Choquette, D., Chabre, H., Slama, F.B., Primo, J., Letrait, M., 
Venot, A. and Jacob, L. (1992) Autoimmunity 12, 61-68. 
Vlahakos, D., Foster, M.H., Ucci, A.A., Barrett, K.J., Datta, S.K. and 
Madaio, M.P. (1992) J. Am. Soc. Nephrol. 2, 1345-1354. 
von Boehmer, H. (1994) Cell 76, 219-228. 
von Sonntag, C. (1987) In: The Chemical Basis of Radiation Biology. Taylor 
and Francis, London. 
Watson, J.D. and Crick, F.H.C. (1953) Nature 171, 737-738. 
144 
Weiss, G., Fuchs, D., Hausen, A., Reibnegger, G., Werner, E.R., Werner-
Felmayer, G., Semenitz, E., Dierich, M.P. and Wachter, H. (1993) FEES 
Lett. 321, 89-92. 
West, S.C. (1992) Annu. Rev. Biochem. 61, 603-640. 
Wilson, R.H., Jurevics, V. and Schram, A.C. (1965) Fed. Proc. Fed. Amer. 
Soc. Exp. Biol. 24, 185. 
Yamasaki, H., Pulkrabek, P., Grunberger, D. and Weinstein, I.B. (1977) 
Cancer Res. 37, 3756-3760. 
Zack, D.J., Yamamoto, K., Wong, A.L., Stempniak, M., French, C. and 
Weisbart, R.H. (1995) J. Immunol. 154, 1987-1994. 
Zarling, D.A., Arndt-Jovin, D.J., Robert-Nicoud, M., Mcintosh, L.P. , 
Thomae, R. and Jovin, T.M. (1984) J. Mol. Biol. 176, 369-415. 
